{
    "questions": [
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38689623"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38689623",
                    "offsetInBeginSection": 498,
                    "offsetInEndSection": 671,
                    "text": "Zotiraciclib, a CDK9 inhibitor, has demonstrated efficacy in glioblastoma treatment in preclinical and clinical studies, showing its potential as a therapeutic breakthrough.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Should Zotiraciclib be used for glioblastoma?",
            "type": "yesno",
            "id": "67e6cf2618b1e36f2e0000d0",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38187079",
                "http://www.ncbi.nlm.nih.gov/pubmed/37541194",
                "http://www.ncbi.nlm.nih.gov/pubmed/38775925",
                "http://www.ncbi.nlm.nih.gov/pubmed/37343519",
                "http://www.ncbi.nlm.nih.gov/pubmed/38563867",
                "http://www.ncbi.nlm.nih.gov/pubmed/32769757",
                "http://www.ncbi.nlm.nih.gov/pubmed/33724119",
                "http://www.ncbi.nlm.nih.gov/pubmed/36924778",
                "http://www.ncbi.nlm.nih.gov/pubmed/39391998",
                "http://www.ncbi.nlm.nih.gov/pubmed/38640780"
            ],
            "snippets": [
                    {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38187079",
                    "offsetInBeginSection": 853,
                    "offsetInEndSection": 942,
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Fezolinetant was recently approved by the FDA for the treatment of moderate-to-severe VMS"
                    },
                    {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37541194",
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 351,
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-class nonhormonal treatment for menopausal hot flashes"
                    },
                    {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38775925",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 258,
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Current treatment options for VMS include fezolinetant, a nonhormonal, selective neurokinin\u00a03 receptor antagonist"
                    },
                    {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37343519",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Fezolinetant is a neurokinin 3 receptor antagonist under investigation for treatment of menopausal symptoms"
                    },
                    {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38563867",
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 277,
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Fezolinetant, a selective neurokinin 3 receptor (NK3R) antagonist, is a potential therapeutic option for mitigating VMS"
                    },
                    {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32769757",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 288,
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "This secondary analysis evaluates effects of fezolinetant on responder rates and patient-reported outcomes (PROs)"
                    },
                    {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33724119",
                    "offsetInBeginSection": 1074,
                    "offsetInEndSection": 1165,
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Fezolinetant is the most advanced NK3R antagonist in terms of stage of clinical development"
                    },
                    {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36924778",
                    "offsetInBeginSection": 3604,
                    "offsetInEndSection": 3730,
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Furthermore, the population studied was diverse and representative of the potential target population for fezolinetant therapy"
                    },
                    {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39391998",
                    "offsetInBeginSection": 747,
                    "offsetInEndSection": 897,
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Here, we report pharmacodynamics and pharmacokinetic properties of fezolinetant as well as its efficacy and safety data from available clinical trials"
                    },
                    {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38640780",
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 518,
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Databases were searched until September 2023 for relevant studies comparing fezolinetant against placebo"
                    }
                ],
            "body": "What is the target of fezolinetant?",
            "type": "factoid",
            "id": "67e5557c18b1e36f2e0000ac",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12606880",
                "http://www.ncbi.nlm.nih.gov/pubmed/34999879",
                "http://www.ncbi.nlm.nih.gov/pubmed/31806244",
                "http://www.ncbi.nlm.nih.gov/pubmed/11139327",
                "http://www.ncbi.nlm.nih.gov/pubmed/21991952",
                "http://www.ncbi.nlm.nih.gov/pubmed/37471692",
                "http://www.ncbi.nlm.nih.gov/pubmed/15168959",
                "http://www.ncbi.nlm.nih.gov/pubmed/33077562",
                "http://www.ncbi.nlm.nih.gov/pubmed/31570176",
                "http://www.ncbi.nlm.nih.gov/pubmed/36420138"
                ],
            "snippets": [
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12606880",
                "offsetInBeginSection": 12,
                "offsetInEndSection": 173,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "Between 1939 and the 1960s, the synthetic estrogen diethylstilbestrol (DES) was given to millions of pregnant women to prevent pregnancy complications and losses"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/34999879",
                "offsetInBeginSection": 12,
                "offsetInEndSection": 170,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "Diethylstilbestrol (DES) is an endocrine-disrupting pharmaceutical prescribed to pregnant women to prevent pregnancy complications between the 1940s and 1970s"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/31806244",
                "offsetInBeginSection": 11,
                "offsetInEndSection": 184,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "Prenatal exposure of women to diethylstilbestrol (DES) has been associated with reproductive tract anomalies, menstrual irregularity, infertility and pregnancy complications"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11139327",
                "offsetInBeginSection": 0,
                "offsetInEndSection": 79,
                "beginSection": "title",
                "endSection": "title",
                "text": "Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy."
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21991952",
                "offsetInBeginSection": 0,
                "offsetInEndSection": 72,
                "beginSection": "title",
                "endSection": "title",
                "text": "Adverse health outcomes in women exposed in utero to diethylstilbestrol."
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/37471692",
                "offsetInBeginSection": 0,
                "offsetInEndSection": 126,
                "beginSection": "title",
                "endSection": "title",
                "text": "Prenatal exposure to diethylstilbestrol has long-lasting, transgenerational impacts on fertility and reproductive development."
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15168959",
                "offsetInBeginSection": 0,
                "offsetInEndSection": 28,
                "beginSection": "title",
                "endSection": "title",
                "text": "Diethylstilbestrol exposure."
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/33077562",
                "offsetInBeginSection": 14,
                "offsetInEndSection": 162,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are two major pregnancy complications, related to chronic uteroplacental hypoperfusion"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/31570176",
                "offsetInBeginSection": 158,
                "offsetInEndSection": 446,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "Prospective cohort study including nulliparous women with primary unexplained infertility, repeated in vitro fertilization (IVF) failure or recurrent spontaneous miscarriage and T-shaped uterus anomaly not diethylstilbestrol-related, diagnosed by 3D ultrasound and diagnostic hysteroscopy"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/36420138",
                "offsetInBeginSection": 0,
                "offsetInEndSection": 277,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "Placenta accreta spectrum disorders (PAS) are severe pregnancy complications that occur when extravillous trophoblast cells (EVTs) invade beyond the uterine inner myometrium and are characterized by hypervascularity on prenatal ultrasound and catastrophic postpartum hemorrhage"
                }
            ],
            "body": "What complication of pregnancy was treated with  Diethylstilbestrol",
            "type": "factoid",
            "id": "6810fef8353a4a2e6b000016",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36931575",
                "http://www.ncbi.nlm.nih.gov/pubmed/35958169",
                "http://www.ncbi.nlm.nih.gov/pubmed/35543710",
                "http://www.ncbi.nlm.nih.gov/pubmed/34261180",
                "http://www.ncbi.nlm.nih.gov/pubmed/33996875",
                "http://www.ncbi.nlm.nih.gov/pubmed/29143504",
                "http://www.ncbi.nlm.nih.gov/pubmed/28491293",
                "http://www.ncbi.nlm.nih.gov/pubmed/31256414",
                "http://www.ncbi.nlm.nih.gov/pubmed/29768275",
                "http://www.ncbi.nlm.nih.gov/pubmed/29744361"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36931575",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Bronchiectasis (BE) is a chronic condition characterized by airway dilation as a consequence of a variety of pathogenic processes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35958169",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "text": "Bronchiectasis (BE) is a chronic condition affecting the bronchial tree.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35543710",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "Bronchiectasis is a chronic condition that is becoming a global health concern.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34261180",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Bronchiectasis is a chronic condition of global relevance resulting in permanent and irreversible structural airway damage.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33996875",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "text": "Bronchiectasis is a chronic condition in which areas of the bronchial tubes become permanently widened predisposing the lungs to infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143504",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "text": "Bronchiectasis is a chronic condition with a prevalence continuously on the rise.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28491293",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "text": "Bronchiectasis is a heterogeneous, chronic condition with many aetiologies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is bronchiectasis a chronic or acute condition?",
            "type": "factoid",
            "id": "680d5e47353a4a2e6b000005",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35843573",
                "http://www.ncbi.nlm.nih.gov/pubmed/35700276",
                "http://www.ncbi.nlm.nih.gov/pubmed/38112963",
                "http://www.ncbi.nlm.nih.gov/pubmed/38091917",
                "http://www.ncbi.nlm.nih.gov/pubmed/39722333"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843573",
                    "offsetInBeginSection": 515,
                    "offsetInEndSection": 671,
                    "text": "biologics like TNF inhibitors (etanercept, infliximab, adalimumab) and IL inhibitors (ustekinumab) have become key compounds in the treatment of depression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843573",
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 844,
                    "text": "Interestingly, treatment with an antidepressant has been found to decrease the TNF- level and improve depression-like behaviors in several preclinical and clinical studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843573",
                    "offsetInBeginSection": 1015,
                    "offsetInEndSection": 1143,
                    "text": "Animal models and clinical studies further support that TNF- inhibitors are effective in ameliorating depression-like behaviors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843573",
                    "offsetInBeginSection": 1144,
                    "offsetInEndSection": 1301,
                    "text": "Moreover, studies showed that peripheral injection of TNF- exhibits depressive symptoms. These symptoms have been improved by treatment with TNF- inhibitors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35700276",
                    "offsetInBeginSection": 1307,
                    "offsetInEndSection": 1419,
                    "text": "Numeric improvements in all PROMIS measures (anxiety, depression, social satisfaction) were seen through day 56.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38112963",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 651,
                    "text": "These interventions have been associated with improvements in mood and related symptoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38091917",
                    "offsetInBeginSection": 318,
                    "offsetInEndSection": 484,
                    "text": "Selective serotonin reuptake inhibitors (SSRIs), a first-line PMDD treatment, reportedly alter gamma-aminobutyric acid (GABA)ergic neuroactive steroid levels in PMDD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38091917",
                    "offsetInBeginSection": 1785,
                    "offsetInEndSection": 1993,
                    "text": "Within the PMDD group, sertraline treatment was associated with a significant increase in luteal phase serum pregnanolone levels and a significantly increased pregnanolone:progesterone ratio, a novel finding.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38112963",
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 790,
                    "text": "There are now enough studies and participants to permit meta-analytic analyses of the actions of these and other anti-inflammatory agents.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39722333",
                    "offsetInBeginSection": 987,
                    "offsetInEndSection": 1035,
                    "text": "more failed antidepressants (mean, 15.0 vs 12.1)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do biopharmaceuticals have a role in the treatment of depression?",
            "type": "yesno",
            "id": "680f4a68353a4a2e6b000007",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37781369",
                "http://www.ncbi.nlm.nih.gov/pubmed/19707374",
                "http://www.ncbi.nlm.nih.gov/pubmed/31215483"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37781369",
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 861,
                    "text": "ASCENIV is an approved IVIG that is manufactured from blending normal source plasma with plasma from donors that possess high antibody titers against RSV and other respiratory pathogens of concern.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19707374",
                    "offsetInBeginSection": 600,
                    "offsetInEndSection": 789,
                    "text": "To date, however, passive immunoprophylaxis with monoclonal antibodies is the only strategy that has demonstrated consistent efficacy in reducing RSV hospitalizations in high-risk children.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37781369",
                    "offsetInBeginSection": 1380,
                    "offsetInEndSection": 1705,
                    "text": "This case series reviews three pediatric patients  5 years of age with immune dysregulation and who were severely ill with RSV. Despite receiving best supportive care, and standard immunoglobulin therapy for some, the patients' clinical status continued to decline. All patients received ASCENIV in an intensive care setting.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37781369",
                    "offsetInBeginSection": 1791,
                    "offsetInEndSection": 1953,
                    "text": "This case series demonstrated that ASCENIV (500mg/kg) administration may have contributed to the treatment outcomes of a less well studied age-cohort of patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Biopharmaceuticals for pediatric bronchiolitis.",
            "type": "factoid",
            "id": "6810cb23353a4a2e6b000012",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39657671",
                "http://www.ncbi.nlm.nih.gov/pubmed/39589170",
                "http://www.ncbi.nlm.nih.gov/pubmed/39587614",
                "http://www.ncbi.nlm.nih.gov/pubmed/39580060",
                "http://www.ncbi.nlm.nih.gov/pubmed/39544929",
                "http://www.ncbi.nlm.nih.gov/pubmed/39463930",
                "http://www.ncbi.nlm.nih.gov/pubmed/39400857",
                "http://www.ncbi.nlm.nih.gov/pubmed/39265565",
                "http://www.ncbi.nlm.nih.gov/pubmed/39211183",
                "http://www.ncbi.nlm.nih.gov/pubmed/39207691"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39657671",
                    "offsetInBeginSection": 577,
                    "offsetInEndSection": 719,
                    "text": "SHIP1-deficient microglia showed altered transcriptional signatures and abnormal synaptic pruning that was dependent on the complement system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39657671",
                    "offsetInBeginSection": 849,
                    "offsetInEndSection": 974,
                    "text": "Induced pluripotent stem cell (iPSC)-derived microglia lacking SHIP1 also showed increased engulfment of synaptic structures.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39589170",
                    "offsetInBeginSection": 1086,
                    "offsetInEndSection": 1306,
                    "text": "Impaired microglial activity damages dopaminergic neurons by diminishing neurotrophic support (e.g., insulin-like growth factor-1) and hinders dopaminergic axon growth through defective phagocytosis and synaptic pruning.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39587614",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "Microglia play a crucial role in brain development and repair by facilitating processes such as synaptic pruning and debris clearance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39580060",
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 929,
                    "text": "They impact normal neural development through various mechanisms contributing to ASD, such as neuroinflammation, and alterations in synaptic formation and pruning.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39544929",
                    "offsetInBeginSection": 1381,
                    "offsetInEndSection": 1573,
                    "text": "Prelimbic chemical deletion or microglia inhibition improved fear memory formation. Further investigation demonstrated that TREM2 regulates microglial phagocytosis, enhancing synaptic pruning.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39463930",
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 296,
                    "text": "dark microglia interact with blood vessels and synapses and perform trogocytosis of pre-synaptic axon terminals.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39463930",
                    "offsetInBeginSection": 324,
                    "offsetInEndSection": 668,
                    "text": "dark microglia in development notably expressed C-type lectin domain family 7 member A (CLEC7a), lipoprotein lipase (LPL) and triggering receptor expressed on myeloid cells 2 (TREM2) and required TREM2, differently from other microglia, suggesting a link between their role in remodeling during development and central nervous system pathology.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39463930",
                    "offsetInBeginSection": 669,
                    "offsetInEndSection": 833,
                    "text": "Together, these results point towards a previously under-appreciated role for dark microglia in synaptic pruning and plasticity during normal postnatal development.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39400857",
                    "offsetInBeginSection": 98,
                    "offsetInEndSection": 358,
                    "text": "Microglia, the resident immunocytes of the CNS, are endowed with UDP-sensitive P2Y6 receptors (P2Y6Rs) which regulate phagocytosis/pruning of excessive synapses during individual development and refine synapses in an activity-dependent manner during adulthood.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are microglia involved in synaptic pruning during development?",
            "type": "yesno",
            "id": "680a083218b1e36f2e00014d",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37580263"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37580263",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "text": "Non-alcoholic fatty liver disease (NAFLD) has replaced chronic hepatitis B as the most common chronic liver disease in China and has now been renamed metabolic dysfunction-associated fatty liver disease (MAFLD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Diasease  (MASLD)?",
            "type": "factoid",
            "id": "67fe5f0918b1e36f2e000144",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39358647",
                "http://www.ncbi.nlm.nih.gov/pubmed/22632132"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39358647",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "Natural killer (NK) cells are frontline defenders against cancer and are capable of recognizing and eliminating tumor cells without prior sensitization or antigen presentation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22632132",
                    "offsetInBeginSection": 1079,
                    "offsetInEndSection": 1224,
                    "text": "Human blood  T-lymphocytes have innate tumor cell killing properties by both antibody-dependent and natural killer receptor-dependent mechanisms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do natural killer (NK) cells require antigen presentation to eliminate cancer cells?",
            "type": "yesno",
            "id": "680a079718b1e36f2e000147",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39730243",
                "http://www.ncbi.nlm.nih.gov/pubmed/39710707",
                "http://www.ncbi.nlm.nih.gov/pubmed/39672553",
                "http://www.ncbi.nlm.nih.gov/pubmed/39658540",
                "http://www.ncbi.nlm.nih.gov/pubmed/39653150",
                "http://www.ncbi.nlm.nih.gov/pubmed/39620588",
                "http://www.ncbi.nlm.nih.gov/pubmed/39523444",
                "http://www.ncbi.nlm.nih.gov/pubmed/39486886",
                "http://www.ncbi.nlm.nih.gov/pubmed/39472714",
                "http://www.ncbi.nlm.nih.gov/pubmed/39461750"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730243",
                    "offsetInBeginSection": 577,
                    "offsetInEndSection": 734,
                    "text": "we summarize the intrinsic, extrinsic, and systemic factors contributing to the formation of 'cold' tumors within the framework of the cancer-immunity cycle.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39710707",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "cGAS-STING pathway stands at the forefront of innate immunity and plays a critical role in regulating adaptive immune responses, making it as a key orchestrator of anti-tumor immunity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39672553",
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 414,
                    "text": "To promote the infiltration of T cells and dendritic cells (DCs) into the tumor, we previously proposed a local cell therapy using chemokine (C-C motif) ligand 19 (CCL19)-expressing immortalized syngeneic immortalized mesenchymal stem cells (syn-iMSC/CCL19).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39672553",
                    "offsetInBeginSection": 678,
                    "offsetInEndSection": 811,
                    "text": "The allo-iMSC/CCL19 therapy exerted drastic antitumor effects, in which the host's T cells were induced to respond to allogeneic MSC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39672553",
                    "offsetInBeginSection": 812,
                    "offsetInEndSection": 1011,
                    "text": "In addition, the allo-iMSC/CCL19 therapy promoted the infiltration of CD103 These results suggest that allo-iMSC/CCL19 therapy exerts dramatic antitumor effects by promoting the infiltration of CD103",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39658540",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 485,
                    "text": "targeting the immunosuppressive effects of macrophages and neutrophils to boost the cancer immunity cycle was clinically less successful.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39653150",
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 630,
                    "text": "This approach not only replenishes DCs in the TEM, but also increases antigen uptake through the attraction between the magnetic particles and promotes DC activation and antigen presentation, thus continuously enhancing the tumor immune cycle.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39653150",
                    "offsetInBeginSection": 925,
                    "offsetInEndSection": 1229,
                    "text": "These antigens were captured by MCM nanoparticles to construct magnetized tumor vaccines. Magnetic M-BMDCs introduced at the tumor site are attracted to these magnetized vaccines, resulting in a significant increase in antigen uptake and activation of DCs, significantly enhancing the tumor immune cycle.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39653150",
                    "offsetInBeginSection": 1230,
                    "offsetInEndSection": 1430,
                    "text": "This co-administration strategy of magnetized vaccines and magnetized BMDCs provides a unique combination therapy for reversing immunosuppressive TEM and enhancing the efficacy of tumor immunotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39620588",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 337,
                    "text": "Most cancer immunotherapies focus on stimulating T-cell-mediated immunity by driving the cancer-immunity cycle, which includes tumor antigen release, antigen presentation, T cell activation, infiltration, and tumor cell killing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the cancer-immunity cycle?",
            "type": "summary",
            "id": "680bc7a718b1e36f2e000156",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37914086",
                "http://www.ncbi.nlm.nih.gov/pubmed/39371251",
                "http://www.ncbi.nlm.nih.gov/pubmed/36698833",
                "http://www.ncbi.nlm.nih.gov/pubmed/38727420"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37914086",
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 267,
                    "text": "Iptacopan (LNP023) is an oral, proximal alternative complement inhibitor that specifically binds to Factor B.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39371251",
                    "offsetInBeginSection": 1008,
                    "offsetInEndSection": 1235,
                    "text": "New proximal complement inhibitors (CI) mainly targeting complement component C3 or factors of the amplification pathway such as pegcetacoplan, danicopan, and iptacopan became available and are meanwhile approved for marketing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36698833",
                    "offsetInBeginSection": 1203,
                    "offsetInEndSection": 1435,
                    "text": "PNH treatment is moving from the intravenous anti-C5 eculizumab to its long-term analog ravulizumab, and to subcutaneous and oral proximal inhibitors (anti-C3 pegcetacoplan, factor D and factor B inhibitors danicopan and iptacopan).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38727420",
                    "offsetInBeginSection": 756,
                    "offsetInEndSection": 947,
                    "text": "Proximal complement inhibitors turned out to be the key to the solution of this problem by targeting components of the proximal complement pathway, avoiding intra and extravascular hemolysis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39371251",
                    "offsetInBeginSection": 1312,
                    "offsetInEndSection": 1481,
                    "text": "A switch from terminal to proximal CI in patients with significant EVH can achieve hemoglobin and ARC normalization and significant improvement in quality of life (QoL).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the mechanism of action of Iptacopan?",
            "type": "summary",
            "id": "67e56f2018b1e36f2e0000b0",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39651421",
                "http://www.ncbi.nlm.nih.gov/pubmed/39210087",
                "http://www.ncbi.nlm.nih.gov/pubmed/39596160",
                "http://www.ncbi.nlm.nih.gov/pubmed/39454314",
                "http://www.ncbi.nlm.nih.gov/pubmed/39069893",
                "http://www.ncbi.nlm.nih.gov/pubmed/38959896",
                "http://www.ncbi.nlm.nih.gov/pubmed/38832422",
                "http://www.ncbi.nlm.nih.gov/pubmed/38691878",
                "http://www.ncbi.nlm.nih.gov/pubmed/38672662",
                "http://www.ncbi.nlm.nih.gov/pubmed/39617677"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39651421",
                    "offsetInBeginSection": 521,
                    "offsetInEndSection": 558,
                    "text": "anti-CD3  anti CD19 BsAb blinatumomab",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39210087",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 275,
                    "text": "Blinatumomab, a CD3/CD19-directed bispecific T cell engager, is reportedly effective for advanced B-cell ALL (B-ALL), even after allo-HCT.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39596160",
                    "offsetInBeginSection": 525,
                    "offsetInEndSection": 623,
                    "text": "T cell-mediated cytotoxicity induced by the CD19-targeting bispecific T-cell engager blinatumomab.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39454314",
                    "offsetInBeginSection": 477,
                    "offsetInEndSection": 605,
                    "text": "Blinatumomab, a bi-specific antibody, is used as a treatment for B-cell acute lymphoblastic leukemia (ALL) by targeting B cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39069893",
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 590,
                    "text": "The purpose of this review is to provide an overview of bispecific antibody treatment including the mechanisms leading to effector T cells targeting tumor-associated antigens,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38959896",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 556,
                    "text": "We show that human plasma cells expressing either fragment crystallizable domain-deficient anti-CD19  anti-CD3 (blinatumomab) or anti-CD33  anti-CD3 bispecific antibodies mediate T cell activation and direct T cell killing of B acute lymphoblastic leukemia or acute myeloid leukemia cell lines in vitro.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38959896",
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 906,
                    "text": "Plasma cells secreting anti-CD19-bispecific antibodies elicited in vivo control of acute lymphoblastic leukemia patient-derived xenografts in immunodeficient mice co-engrafted with autologous T cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38832422",
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 611,
                    "text": "Blinatumomab is a widely available CD3-CD19 BiTE that has dramatically changed the landscape of therapy for some children with precursor-B acute lymphoblastic leukemias (B-ALL) and lymphoblastic lymphomas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38691878",
                    "offsetInBeginSection": 1206,
                    "offsetInEndSection": 1266,
                    "text": "blinatumomab, a bispecific anti-CD3/anti-CD19 T cell engager",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38672662",
                    "offsetInBeginSection": 713,
                    "offsetInEndSection": 817,
                    "text": "FDA approved blinatumomab, a TCE directed to CD3 and CD19 for treatment of acute lymphoblastic leukemia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the targets of blinatumomab?",
            "type": "list",
            "id": "67e5749b18b1e36f2e0000b5",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39515565"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39515565",
                    "offsetInBeginSection": 874,
                    "offsetInEndSection": 1094,
                    "text": "However, careful attention is required to delineate its long-term safety profile, explore its potential in special populations, unravel its adjunctive therapeutic roles, and elucidate its mechanisms in pediatric cohorts.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can GLP-1 receptor agonists be used for obesity in children under 10 years of age?",
            "type": "yesno",
            "id": "6810f6f0353a4a2e6b000015",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39730457",
                "http://www.ncbi.nlm.nih.gov/pubmed/39713469",
                "http://www.ncbi.nlm.nih.gov/pubmed/39647667",
                "http://www.ncbi.nlm.nih.gov/pubmed/39615775",
                "http://www.ncbi.nlm.nih.gov/pubmed/39610915",
                "http://www.ncbi.nlm.nih.gov/pubmed/39523052"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730457",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "text": "Drug addiction is a multifactorial syndrome in which genetic predispositions and exposure to environmental stressors constitute major risk factors for the early onset, escalation, and relapse of addictive behaviors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730457",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 433,
                    "text": "the genetic factors that make certain individuals particularly sensitive to stress and, thereby, more vulnerable to becoming addicted are unknown.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730457",
                    "offsetInBeginSection": 1189,
                    "offsetInEndSection": 1421,
                    "text": "genetic variation influences chronic stress-induced behavioral outcomes such as social and approach-avoidance behaviors, reward responses, as well as morphine sensitivity, and is likely to modulate the development of drug addiction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39713469",
                    "offsetInBeginSection": 1391,
                    "offsetInEndSection": 1548,
                    "text": "Permutation analyses did not identify associations between behavior and single gene expression when evaluated overall, or between our ascertained phenotypes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39713469",
                    "offsetInBeginSection": 1549,
                    "offsetInEndSection": 1851,
                    "text": "However, weighted genome correlation network analysis (WGCNA) and gene set enrichment analysis (GSEA) determined several gene modules linked to escalated fentanyl intake, including genes coding for voltage-gated potassium channels, calcium channels, and genes involved in excitatory synaptic signaling.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39713469",
                    "offsetInBeginSection": 1852,
                    "offsetInEndSection": 1991,
                    "text": "Transcription factor analyses identified EZH2 and JARID2 as potential transcriptional regulators associated with escalated fentanyl intake.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39713469",
                    "offsetInBeginSection": 1992,
                    "offsetInEndSection": 2138,
                    "text": "Genome-wide association study (GWAS) term categories were also generated and positively associated with terms relating to substance use disorders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39647667",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "Mu-opioid receptors (MORs) in the amygdala and striatum are important in addictive and rewarding behaviors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39647667",
                    "offsetInBeginSection": 108,
                    "offsetInEndSection": 387,
                    "text": "The transcription factor Foxp2 is a genetic marker of intercalated (ITC) cells in the amygdala and a subset of striatal medium spiny neurons (MSNs), both of which express MORs in wild-type mice and are neuronal subpopulations of potential relevance to alcohol-drinking behaviors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39615775",
                    "offsetInBeginSection": 621,
                    "offsetInEndSection": 1007,
                    "text": "We identified 211 highly interrelated genes identified by genome-wide association studies or dysregulation in the dorsolateral prefrontal cortex of people who died of opioid overdose that implicated the Akt, BDNF (brain-derived neurotrophic factor), and ERK (extracellular signal-regulated kinase) pathways, identifying 414 drugs targeting 48 of these opioid addiction-associated genes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the genetic basis of addiction?",
            "type": "summary",
            "id": "67fbe4d718b1e36f2e00011d",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39724784",
                "http://www.ncbi.nlm.nih.gov/pubmed/39607450",
                "http://www.ncbi.nlm.nih.gov/pubmed/39570554",
                "http://www.ncbi.nlm.nih.gov/pubmed/39528608",
                "http://www.ncbi.nlm.nih.gov/pubmed/39409970",
                "http://www.ncbi.nlm.nih.gov/pubmed/39214103",
                "http://www.ncbi.nlm.nih.gov/pubmed/39099033",
                "http://www.ncbi.nlm.nih.gov/pubmed/39071633",
                "http://www.ncbi.nlm.nih.gov/pubmed/38992201",
                "http://www.ncbi.nlm.nih.gov/pubmed/38896238"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724784",
                    "offsetInBeginSection": 583,
                    "offsetInEndSection": 704,
                    "text": "Radiomics and deep learning models were examined to predict the OS time by analyzing the GTV, clinical CTV, and CTVmodel.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39607450",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "text": "To assess the effect of different intensity standardisation techniques (ISTs) and ComBat batch sizes on radiomics survival model performance and stability in a heterogenous, multi-centre cohort of patients with glioblastoma (GBM).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39607450",
                    "offsetInBeginSection": 1175,
                    "offsetInEndSection": 1351,
                    "text": "HM and WS produced the highest relative increase in model discrimination, explained variation and model fit but IST choice did not greatly impact on stability, nor calibration.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39607450",
                    "offsetInBeginSection": 1352,
                    "offsetInEndSection": 1555,
                    "text": "Larger ComBat batches improved discrimination, model fit, and explained variation but higher MBS (reduced sample size) reduced stability (across all performance metrics) and reduced calibration accuracy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39607450",
                    "offsetInBeginSection": 2135,
                    "offsetInEndSection": 2414,
                    "text": "Radiomics risk prediction models in real-world, multicentre contexts could be improved by ComBat and ISTs, however, this degrades calibration and prediction stability and this must be thoroughly investigated before patients can be accurately separated into different risk groups.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39570554",
                    "offsetInBeginSection": 1621,
                    "offsetInEndSection": 1790,
                    "text": "Integrated radiomics, tissue, and plasma-based analyses, may potentially uncover immunotherapeutic response signatures, enabling early, adaptive therapeutic adjustments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39528608",
                    "offsetInBeginSection": 521,
                    "offsetInEndSection": 613,
                    "text": "A six-features radiomics prognostic model was created to calculate the radiomics score (RS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39528608",
                    "offsetInBeginSection": 614,
                    "offsetInEndSection": 725,
                    "text": "High RS (HR = 3.718, 95%CI: 2.222 - 6.220, P < 0.001) was an independent risk factor for overall survival (OS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39528608",
                    "offsetInBeginSection": 726,
                    "offsetInEndSection": 1056,
                    "text": "The correlation between RS and OS was externally verified based on the First Affiliated Hospital of Fujian Medical University cohorts (n = 93; HR = 2.015, 95% CI: 1.079 - 3.762, P = 0.028) and the Second Affiliated Hospital of Zhejiang University School of Medicine cohorts (n = 126; HR = 1.779, 95% CI: 1.023 - 3.091, P = 0.041).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39409970",
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 384,
                    "text": "From each patient's tumor volume, 660 radiomic features (RFs) were extracted and subjected to robustness analysis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are radiomic features useful in predicting survival in glioblastoma patients?",
            "type": "yesno",
            "id": "680a237618b1e36f2e000152",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35371352",
                "http://www.ncbi.nlm.nih.gov/pubmed/37681263",
                "http://www.ncbi.nlm.nih.gov/pubmed/38722512",
                "http://www.ncbi.nlm.nih.gov/pubmed/34094745",
                "http://www.ncbi.nlm.nih.gov/pubmed/37639341"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35371352",
                    "offsetInBeginSection": 714,
                    "offsetInEndSection": 840,
                    "text": "The treatment of patients with acute liver failure with N-acetylcysteine improved transplant-free survival and length of stay.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37681263",
                    "offsetInBeginSection": 62,
                    "offsetInEndSection": 182,
                    "text": "N-acetylcysteine (NAC) is effective at preventing liver injury in most patients when started shortly after the overdose.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38722512",
                    "offsetInBeginSection": 1276,
                    "offsetInEndSection": 1485,
                    "text": "if etiology-specific treatment (antivirals for ALF related to hepatitis B virus (HBV) or Herpes simplex virus (HSV) or N-acetylcysteine for paracetamol) is available, then the outcome with treatment is better.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34094745",
                    "offsetInBeginSection": 855,
                    "offsetInEndSection": 1245,
                    "text": "Levofloxacin was discontinued immediately, and evidence-based treatment per society guidelines from The American Association for the Study of Liver Diseases consisting of IV n-acetylcysteine as well as lactulose and rifaximin was initiated. Such medical management resulted in clinical resolution of his ALF, but he had a poor overall prognosis and eventually succumbed to critical illness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37639341",
                    "offsetInBeginSection": 1235,
                    "offsetInEndSection": 1305,
                    "text": "administration of N-acetylcysteine in acute liver failure (one study);",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "In patients with acute liver failure associated with  paracetamol overdose does  Nacetylcysteine treatment improve survival?.",
            "type": "yesno",
            "id": "68110110353a4a2e6b000018",
            "ideal_answer": "",
            "exact_answer": ""
        },
        
            {
                "documents": [
                    "http://www.ncbi.nlm.nih.gov/pubmed/38719503",
                    "http://www.ncbi.nlm.nih.gov/pubmed/24789119",
                    "http://www.ncbi.nlm.nih.gov/pubmed/18035199",
                    "http://www.ncbi.nlm.nih.gov/pubmed/26171905",
                    "http://www.ncbi.nlm.nih.gov/pubmed/35534039"
                ],
                "snippets": [
                    {
                        "document": "http://www.ncbi.nlm.nih.gov/pubmed/38719503",
                        "offsetInBeginSection": 389,
                        "offsetInEndSection": 564,
                        "text": "Our RCT will address some of these unmet needs by evaluating whether the novel mucoactive agent, erdosteine, has a therapeutic role in children and adults with bronchiectasis.",
                        "beginSection": "abstract",
                        "endSection": "abstract"
                    },
                    {
                        "document": "http://www.ncbi.nlm.nih.gov/pubmed/38719503",
                        "offsetInBeginSection": 564,
                        "offsetInEndSection": 767,
                        "text": "Our primary aim is to determine in children and adults aged 2-49 years with bronchiectasis whether regular erdosteine over a 12-month period reduces acute respiratory exacerbations compared with placebo.",
                        "beginSection": "abstract",
                        "endSection": "abstract"
                    },
                    {
                        "document": "http://www.ncbi.nlm.nih.gov/pubmed/38719503",
                        "offsetInBeginSection": 768,
                        "offsetInEndSection": 914,
                        "text": "Our primary hypothesis is that people with bronchiectasis who regularly use erdosteine will have fewer exacerbations than those receiving placebo.",
                        "beginSection": "abstract",
                        "endSection": "abstract"
                    },
                    {
                        "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789119",
                        "offsetInBeginSection": 2342,
                        "offsetInEndSection": 2642,
                        "text": "In a single small, blinded but not placebo-controlled trial of older (> 55 years) participants with stable bronchiectasis and mucus hypersecretion, erdosteine combined with physiotherapy over a 15-day period improved spirometry and sputum purulence more effectively compared with physiotherapy alone.",
                        "beginSection": "abstract",
                        "endSection": "abstract"
                    },
                    {
                        "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789119",
                        "offsetInBeginSection": 4086,
                        "offsetInEndSection": 4238,
                        "text": "Similarly, erdosteine may be a useful adjunct to physiotherapy in stable patients with mucus hypersecretion, but robust longer-term trials are required.",
                        "beginSection": "abstract",
                        "endSection": "abstract"
                    },
                    {
                        "document": "http://www.ncbi.nlm.nih.gov/pubmed/18035199",
                        "offsetInBeginSection": 414,
                        "offsetInEndSection": 634,
                        "text": "The objective of this study was to test the effectiveness of oral erdosteine in treating elderly patients with bronchiectasis and chronic mucus hypersecretion who have been referred to a pulmonary rehabilitation program.",
                        "beginSection": "abstract",
                        "endSection": "abstract"
                    },
                    {
                        "document": "http://www.ncbi.nlm.nih.gov/pubmed/18035199",
                        "offsetInBeginSection": 942,
                        "offsetInEndSection": 1107,
                        "text": "Group 1 consisted of those patients receiving PO erdosteine 225 mg BID and chest physiotherapy; group 2 comprised those patients receiving chest physiotherapy alone.",
                        "beginSection": "abstract",
                        "endSection": "abstract"
                    },
                    {
                        "document": "http://www.ncbi.nlm.nih.gov/pubmed/18035199",
                        "offsetInBeginSection": 2512,
                        "offsetInEndSection": 2621,
                        "text": "The improvement in MVP observed in group 1 was significantly better than that observed in group 2 (P < 0.05).",
                        "beginSection": "abstract",
                        "endSection": "abstract"
                    },
                    {
                        "document": "http://www.ncbi.nlm.nih.gov/pubmed/26171905",
                        "offsetInBeginSection": 4133,
                        "offsetInEndSection": 4399,
                        "text": "In the review of mucolytics versus placebo, relevant outcomes were not reported for erdosteine comparisons and no significant adverse effects were reported for bromhexine, though adverse events were associated with RhDNase (OR 28.19, 95% CI 3.77 to 210.85, 1 study).",
                        "beginSection": "abstract",
                        "endSection": "abstract"
                    },
                    {
                        "document": "http://www.ncbi.nlm.nih.gov/pubmed/35534039",
                        "offsetInBeginSection": 369,
                        "offsetInEndSection": 583,
                        "text": "Our planned RCT seeks to address some of these unmet needs by employing a currently prescribed (but unapproved for long-term use in PCD) macrolide antibiotic (azithromycin) and a novel mucolytic agent (erdosteine).",
                        "beginSection": "abstract",
                        "endSection": "abstract"
                    }
                ],
            "body": "What is the relationship between bronchiectasis and Erdosteine?",
            "type": "summary",
            "id": "680d5f2a353a4a2e6b000006",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39650236",
                "http://www.ncbi.nlm.nih.gov/pubmed/39602602",
                "http://www.ncbi.nlm.nih.gov/pubmed/39718015",
                "http://www.ncbi.nlm.nih.gov/pubmed/39738517",
                "http://www.ncbi.nlm.nih.gov/pubmed/39704607",
                "http://www.ncbi.nlm.nih.gov/pubmed/39688830",
                "http://www.ncbi.nlm.nih.gov/pubmed/39717671",
                "http://www.ncbi.nlm.nih.gov/pubmed/39664753",
                "http://www.ncbi.nlm.nih.gov/pubmed/39545376",
                "http://www.ncbi.nlm.nih.gov/pubmed/39708260"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39650236",
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 697,
                    "text": "extracting a comprehensive set of radiomics features. The dataset included shape, texture, and intensity metrics from segmented vertebrae,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39602602",
                    "offsetInBeginSection": 549,
                    "offsetInEndSection": 658,
                    "text": "The radiomics features included first-order statistics, size- and shape-based features, and texture features.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39718015",
                    "offsetInBeginSection": 1014,
                    "offsetInEndSection": 1108,
                    "text": "wavelet, three-dimensional local binary patterns, and logarithmic sigma of gray-level variance",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39738517",
                    "offsetInBeginSection": 713,
                    "offsetInEndSection": 839,
                    "text": "For feature extraction, 101 radiomic features were extracted from the tumour regions using the 'pyradiomics' module in Python.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39704607",
                    "offsetInBeginSection": 838,
                    "offsetInEndSection": 992,
                    "text": "Cardiac dose-volume histograms, demographic data, echocardiographic parameters, and ultrasound imaging radiomics features were collected for all patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39688830",
                    "offsetInBeginSection": 1588,
                    "offsetInEndSection": 1668,
                    "text": "16 morphology-related imaging histological features were extracted for analysis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39717671",
                    "offsetInBeginSection": 483,
                    "offsetInEndSection": 610,
                    "text": "Additionally, statistics-based radiomic algorithms were applied to quantify differences in the lesion texture on US-PAT images.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39664753",
                    "offsetInBeginSection": 734,
                    "offsetInEndSection": 863,
                    "text": "Imaging features, like original_shape_Maximum2D, DiameterRow, Original_Shape_Elongation, etc. predict the prognosis of TN on PBC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39545376",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 543,
                    "text": "computed on feature transformations (306 radiomic features) of abnormal image regions observed over time.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39708260",
                    "offsetInBeginSection": 1120,
                    "offsetInEndSection": 1250,
                    "text": "Models incorporating radiomics had numerically better performance than those incorporating manual measured radiological variables.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What types of features are typically extracted in radiomics?",
            "type": "list",
            "id": "680a087218b1e36f2e00014f",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39734479",
                "http://www.ncbi.nlm.nih.gov/pubmed/39684473",
                "http://www.ncbi.nlm.nih.gov/pubmed/39720231",
                "http://www.ncbi.nlm.nih.gov/pubmed/39696453",
                "http://www.ncbi.nlm.nih.gov/pubmed/39664386",
                "http://www.ncbi.nlm.nih.gov/pubmed/39667222",
                "http://www.ncbi.nlm.nih.gov/pubmed/39663685",
                "http://www.ncbi.nlm.nih.gov/pubmed/39740876",
                "http://www.ncbi.nlm.nih.gov/pubmed/39665218",
                "http://www.ncbi.nlm.nih.gov/pubmed/39741180"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734479",
                    "offsetInBeginSection": 314,
                    "offsetInEndSection": 458,
                    "text": "DCs, as key antigen-presenting cells, play a critical role in shaping immune responses by influencing T-cell activation and cytokine production.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39684473",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Dendritic cells (DCs) are known to be major antigen-presenting cells, and lymph nodes (LNs) play an important role in DC-mediated immune response.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39720231",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "In recent years, increasing evidence has highlighted the critical role of myeloid cells, specifically those that present antigen (APCs) in health and disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39696453",
                    "offsetInBeginSection": 278,
                    "offsetInEndSection": 421,
                    "text": "As antigen-presenting cells within the innate immune system, macrophages are pivotal in tumor immunotherapy through their phagocytic functions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39664386",
                    "offsetInBeginSection": 201,
                    "offsetInEndSection": 378,
                    "text": "While MHC-II genes are typically expressed by professional antigen-presenting cells, they are also expressed in tumor cells, potentially facilitating antitumor immune responses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39667222",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 201,
                    "text": "Dendritic cells (DCs) play a crucial role in guiding T-cell responses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39663685",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 364,
                    "text": "Lymph nodes are crucial immune foci as the primary target for cancer immunotherapy. However, the anti-tumor functions of tumor-draining lymph nodes (TDLNs) are critically suppressed by tumors. Here, a novel spatiotemporal nano-regulator is presented, designed to modulate the dendritic cells (DCs) in TDLNs, establishing a supportive niche for immune surveillance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740876",
                    "offsetInBeginSection": 925,
                    "offsetInEndSection": 1046,
                    "text": "The local intestinal immune system consists primarily of macrophages, antigen-presenting cells, and natural killer cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39665218",
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 299,
                    "text": "The formation of FVIII inhibitors is a CD4+ T-cell dependent mechanism which includes antigen presenting cells (APCs), B- and T-helper lymphocytes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39665218",
                    "offsetInBeginSection": 300,
                    "offsetInEndSection": 405,
                    "text": "APCs present FVIII derived peptides on major histocompatibility complex class II (MHC-II) to CD4+ Tcells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which cells are the primary antigen-presenting cells?",
            "type": "factoid",
            "id": "680a07a418b1e36f2e000148",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39732412",
                "http://www.ncbi.nlm.nih.gov/pubmed/39731790",
                "http://www.ncbi.nlm.nih.gov/pubmed/39699222",
                "http://www.ncbi.nlm.nih.gov/pubmed/39699212",
                "http://www.ncbi.nlm.nih.gov/pubmed/39666392",
                "http://www.ncbi.nlm.nih.gov/pubmed/39620199",
                "http://www.ncbi.nlm.nih.gov/pubmed/39560407",
                "http://www.ncbi.nlm.nih.gov/pubmed/39522370",
                "http://www.ncbi.nlm.nih.gov/pubmed/39494757",
                "http://www.ncbi.nlm.nih.gov/pubmed/39489364"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39732412",
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 529,
                    "text": "Thus, we investigated the relationship between oxidative stress and SIPS sentinel markers in untreated Schistosoma mansoni-infected mice and those receiving praziquantel (Pz)-based reference treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39732412",
                    "offsetInBeginSection": 1138,
                    "offsetInEndSection": 1335,
                    "text": "These abnormalities were blocked by Pz treatment, which prevented infection chronification and the decline in hepatocytes proliferative potential, stimulating granulomatous inflammation resolution.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39732412",
                    "offsetInBeginSection": 1618,
                    "offsetInEndSection": 1855,
                    "text": "pharmacological blockade of infection and granulomatous inflammation is essential to prevent these premature senescence markers associated with hepatocytes replicative disorders, stimulating liver regeneration in schistosomiasis mansoni.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39731790",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "For over three decades, praziquantel (PZQ) has been the mainstay chemotherapy for prevention and treatment of schistosomiasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39699222",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "Schistosomiasis is commonly managed using the praziquantel, but it is only effective against adult worms and duration of action is short.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39699212",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "Praziquantel alone is insufficient for the control of schistosomiasis due to poor efficacy against juvenile worms and increasing concerns about the risk of drug resistance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39666392",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 840,
                    "text": "Participants were treated with PZQ (or placebo) at weeks 8, 17, and 30.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39620199",
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 310,
                    "text": "The existing reliance on a solitary medication (Praziquantel) gives rise to concerns about drug resistance and possible side effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39560407",
                    "offsetInBeginSection": 1266,
                    "offsetInEndSection": 1363,
                    "text": "Favorably praziquantel (PZQ) is a medication with excellent chemopreventive treatment compliance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39522370",
                    "offsetInBeginSection": 157,
                    "offsetInEndSection": 400,
                    "text": "The goal of this study was to investigate the anti-schistosomal effect of Spirulina platensis (SP) and Spirulina loaded niosomes (SPN), either in the presence or absence of praziquantel (PZQ) against S. mansoni in experimentally infected mice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the pharmacological treatment of urinary schistosomiasis?",
            "type": "factoid",
            "id": "680f4c63353a4a2e6b00000d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39739648",
                "http://www.ncbi.nlm.nih.gov/pubmed/39733842",
                "http://www.ncbi.nlm.nih.gov/pubmed/39733798",
                "http://www.ncbi.nlm.nih.gov/pubmed/39729440",
                "http://www.ncbi.nlm.nih.gov/pubmed/39726974",
                "http://www.ncbi.nlm.nih.gov/pubmed/39710789",
                "http://www.ncbi.nlm.nih.gov/pubmed/39680691",
                "http://www.ncbi.nlm.nih.gov/pubmed/39674485",
                "http://www.ncbi.nlm.nih.gov/pubmed/39652283",
                "http://www.ncbi.nlm.nih.gov/pubmed/39640265"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739648",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "Approximately 50% of the patients with ulcerative colitis (UC) are primarily nonresponsive to anti-tumor necrosis factor (TNF) therapy or lose their responsiveness over time.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39733842",
                    "offsetInBeginSection": 1684,
                    "offsetInEndSection": 1789,
                    "text": "Fecal microbiota transplantation may also improve behavioral symptoms and restore gut microbiota balance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39733842",
                    "offsetInBeginSection": 1790,
                    "offsetInEndSection": 1966,
                    "text": "The review emphasizes the need for further research on gut microbiota modification as a potential therapeutic approach for ASD, highlighting its potential in clinical settings.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39733798",
                    "offsetInBeginSection": 1147,
                    "offsetInEndSection": 1367,
                    "text": "modulating the gut microbiota through diet, lifestyle changes, prebiotics, probiotics, or fecal microbiota transplantation may contribute to gut homeostasis and the management of obesity and its associated comorbidities.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39729440",
                    "offsetInBeginSection": 1340,
                    "offsetInEndSection": 1603,
                    "text": "Faecal microbiota transplantation has been effective for dysbiosis in non-critically ill patients with recurrent C. difficile infections and it is plausible to hypothesize that it will be equally effective for symptoms of dysbiosis in the critically ill patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726974",
                    "offsetInBeginSection": 346,
                    "offsetInEndSection": 480,
                    "text": "Fecal microbiota transplantation (FMT) is an almost effective and safe treatment option for recurrent Clostridium difficile infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726974",
                    "offsetInBeginSection": 631,
                    "offsetInEndSection": 748,
                    "text": "Thus, incorporating host microbiota-based therapies could offer an additional treatment option for glaucoma patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39710789",
                    "offsetInBeginSection": 3472,
                    "offsetInEndSection": 3767,
                    "text": "interventions targeting the gut microbiota and its metabolites, such as through fecal microbiota transplantation (FMT) and the application of probiotics to alter the composition of the gut microbiota and enhance the production of beneficial metabolites, present a promising therapeutic strategy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39680691",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "Fecal microbiota transplantation has been vital for establishing whether host phenotypes can be conferred through the microbiome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39674485",
                    "offsetInBeginSection": 551,
                    "offsetInEndSection": 662,
                    "text": "Hypoglycemic effects were evaluated after microbial community restoration via fecal microbiota transplantation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What diseases are treated with fecal transplants?",
            "type": "list",
            "id": "6810daad353a4a2e6b000013",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38345118"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38345118",
                    "offsetInBeginSection": 1415,
                    "offsetInEndSection": 1629,
                    "text": "Single placebo-controlled studies show the efficacy of sertraline, escitalopram and citalopram in the treatment of depression in patients <18 years of age, making them important treatment options worth considering.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can sertraline be used in children under 10?",
            "type": "yesno",
            "id": "6810c27b353a4a2e6b000010",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39411283",
                "http://www.ncbi.nlm.nih.gov/pubmed/39229234",
                "http://www.ncbi.nlm.nih.gov/pubmed/39712644",
                "http://www.ncbi.nlm.nih.gov/pubmed/39679875",
                "http://www.ncbi.nlm.nih.gov/pubmed/39556113",
                "http://www.ncbi.nlm.nih.gov/pubmed/39551273",
                "http://www.ncbi.nlm.nih.gov/pubmed/39529750",
                "http://www.ncbi.nlm.nih.gov/pubmed/39526104",
                "http://www.ncbi.nlm.nih.gov/pubmed/39522697",
                "http://www.ncbi.nlm.nih.gov/pubmed/39515586"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39411283",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208,
                    "text": "Neurodegenerative diseases such as Alzheimer's disease and polyglutamine diseases are characterized by abnormal accumulation of misfolded proteins, leading to neuronal dysfunction and subsequent neuron death.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39229234",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "The appearance of misfolded and aggregated proteins is a pathological hallmark of numerous neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death?",
            "type": "yesno",
            "id": "67fbd58c18b1e36f2e00010e",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39201067",
                "http://www.ncbi.nlm.nih.gov/pubmed/36563919"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39201067",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "Takotsubo syndrome (TTS), also known as the broken-heart syndrome, is a reversible condition typically observed in female patients presenting for acute coronary syndromes (ACS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36563919",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Takotsubo syndrome (TTS) is being increasingly recognized globally with a female sex predilection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is takotsubo cardiomyopathy more common in men?",
            "type": "yesno",
            "id": "67e26b0b18b1e36f2e000073",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39574145",
                "http://www.ncbi.nlm.nih.gov/pubmed/39383614",
                "http://www.ncbi.nlm.nih.gov/pubmed/39169860",
                "http://www.ncbi.nlm.nih.gov/pubmed/38926376",
                "http://www.ncbi.nlm.nih.gov/pubmed/38634518",
                "http://www.ncbi.nlm.nih.gov/pubmed/38478749",
                "http://www.ncbi.nlm.nih.gov/pubmed/38465585",
                "http://www.ncbi.nlm.nih.gov/pubmed/38285291",
                "http://www.ncbi.nlm.nih.gov/pubmed/38131700",
                "http://www.ncbi.nlm.nih.gov/pubmed/38110995"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39574145",
                    "offsetInBeginSection": 915,
                    "offsetInEndSection": 1073,
                    "text": "Furthermore, we observed that autistic females differed from autistic males in the non-social condition and from non-autistic females in the social condition.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39383614",
                    "offsetInBeginSection": 693,
                    "offsetInEndSection": 893,
                    "text": "Findings revealed no significant differences in general intellectual functioning (full-scale IQ), verbal comprehension, working memory, or processing speed between boys and girls in children with ASD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39383614",
                    "offsetInBeginSection": 894,
                    "offsetInEndSection": 1048,
                    "text": "Boys showed an advantage only in the perceptual reasoning index. At the subtest level, boys outperformed on certain tasks, while girls excelled in others.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39169860",
                    "offsetInBeginSection": 391,
                    "offsetInEndSection": 657,
                    "text": "Characterizing these differences is important for autism identification in girls, as SIs in autistic girls may often be overlooked by caregivers, teachers, and clinicians due to their more \"typical\" and more socially oriented content areas compared to autistic boys.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39169860",
                    "offsetInBeginSection": 1281,
                    "offsetInEndSection": 1464,
                    "text": "Categories with significant gender differences fell along typical gender lines (e.g., more boys interested in math and construction, more girls interested in animals and arts/crafts).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38926376",
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 742,
                    "text": "Fine motor and personal-social development quotient in boys with ASD were lower than those in girls with ASD (",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38634518",
                    "offsetInBeginSection": 1207,
                    "offsetInEndSection": 1383,
                    "text": "Females compared to males were overrepresented in unpaid daily activities (e.g., study, volunteer, housemaker) and work incapacitation, and underrepresented in paid employment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38478749",
                    "offsetInBeginSection": 1060,
                    "offsetInEndSection": 1207,
                    "text": "Autistic girls and boys demonstrate largely consistent gender differences in their language use across in-person and online communication contexts.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38478749",
                    "offsetInBeginSection": 1208,
                    "offsetInEndSection": 1542,
                    "text": "Interestingly, most of the significant gender differences previously reported in neurotypical communicators were not seen in this sample of autistic adolescents, suggesting that perhaps autistic individuals may linguistically express gender characteristics to a different extent or in a different manner than neurotypical individuals.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38465585",
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 310,
                    "text": "screening and diagnosis at a later age can be challenging, particularly in girls who exhibit a wider range of behaviors and characteristics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Differential traits of autism spectrum disorders in girls.",
            "type": "list",
            "id": "67fbe10618b1e36f2e000111",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39540072",
                "http://www.ncbi.nlm.nih.gov/pubmed/38460107",
                "http://www.ncbi.nlm.nih.gov/pubmed/39236468",
                "http://www.ncbi.nlm.nih.gov/pubmed/38622003",
                "http://www.ncbi.nlm.nih.gov/pubmed/38543128",
                "http://www.ncbi.nlm.nih.gov/pubmed/38472696",
                "http://www.ncbi.nlm.nih.gov/pubmed/39462720",
                "http://www.ncbi.nlm.nih.gov/pubmed/39415561",
                "http://www.ncbi.nlm.nih.gov/pubmed/38698873",
                "http://www.ncbi.nlm.nih.gov/pubmed/39731508"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39540072",
                    "offsetInBeginSection": 734,
                    "offsetInEndSection": 825,
                    "text": "dual orexin receptors antagonists (DORA) such as daridorexant, lemborexant, and suvorexant.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38460107",
                    "offsetInBeginSection": 594,
                    "offsetInEndSection": 652,
                    "text": " dual orexin receptor antagonist (suvorexant) monotherapy,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39236468",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "text": "Dual orexin receptor antagonists (DORAs) are approved for the treatment of sleep onset and/or sleep maintenance insomnia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38622003",
                    "offsetInBeginSection": 1238,
                    "offsetInEndSection": 1436,
                    "text": "Dual orexin receptor antagonists (DORAs) such as daridorexant, lemborexant, and suvorexant, represent a novel approach to insomnia treatment by inhibiting wakefulness rather than enhancing sedation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38543128",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "Daridorexant (dari), as the first dual orexin receptor antagonist (DORA) marketed in Europe, offers a novel therapeutic approach to insomnia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38472696",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Daridorexant, a dual orexin receptor antagonist was recently approved for the treatment of insomnia at doses up to 50 mg once per night.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39462720",
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 918,
                    "text": "Lemborexant demonstrated potential in improving circadian rhythm parameters, particularly in patients with irregular sleep-wake rhythm disorder (ISWRD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39415561",
                    "offsetInBeginSection": 1076,
                    "offsetInEndSection": 1295,
                    "text": "Current evidence suggests a possible benefit of ramelteon or melatonin, dexmedetomidine for patients in the ICU setting, and DORAs as therapeutic options for the re-regulation of sleep-wake cycle disruption in delirium.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38698873",
                    "offsetInBeginSection": 643,
                    "offsetInEndSection": 772,
                    "text": "This participant was treated with a dual orexin receptor antagonist, suvorexant (Belsomra), currently approved to treat insomnia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39731508",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Preliminary examination of orexin receptor antagonism with suvorexant in individuals with Methamphetamine use disorder: a case series study.",
                    "beginSection": "title",
                    "endSection": "title"
                }
            ],
            "body": "Please list the DORA type drugs",
            "type": "list",
            "id": "6805568118b1e36f2e000145",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39734431",
                "http://www.ncbi.nlm.nih.gov/pubmed/39710430",
                "http://www.ncbi.nlm.nih.gov/pubmed/39632893",
                "http://www.ncbi.nlm.nih.gov/pubmed/39621974",
                "http://www.ncbi.nlm.nih.gov/pubmed/39615812",
                "http://www.ncbi.nlm.nih.gov/pubmed/39598297",
                "http://www.ncbi.nlm.nih.gov/pubmed/39595868",
                "http://www.ncbi.nlm.nih.gov/pubmed/39560415",
                "http://www.ncbi.nlm.nih.gov/pubmed/39523631",
                "http://www.ncbi.nlm.nih.gov/pubmed/39512584"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734431",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 364,
                    "text": "A biomarker of spinal disinhibition is impaired H-reflex rate-dependent depression (HRDD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734431",
                    "offsetInBeginSection": 901,
                    "offsetInEndSection": 1114,
                    "text": "We demonstrate for the first time that people with FMS show evidence of spinal disinhibition, which is most dominant in shorter duration of disease and may represent a putative mechanism of pain generation in FMS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39710430",
                    "offsetInBeginSection": 1224,
                    "offsetInEndSection": 1374,
                    "text": "Patients in tA were more likely to be male, have a university degree, have white-collar jobs, have positive HLA B27 status and have less fibromyalgia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39632893",
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 291,
                    "text": "Since mitochondria are the main source of cellular energy, we hypothesized that fibromyalgia syndrome (FMS) could be linked to mitochondrial impairment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39632893",
                    "offsetInBeginSection": 1040,
                    "offsetInEndSection": 1359,
                    "text": "We demonstrated that patients with FMS had an impaired mitochondrial function. Additionally, we found a mild correlation between the widespread pain index and the BHI, possibly indicating that the altered mitochondrial function, in these patients, narrows musculoskeletal rather than central nervous system involvement.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39621974",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Fibromyalgia is a complex condition that has long puzzled the medical community.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39621974",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 201,
                    "text": "Hypotheses to explain the chronic widespread pain associated with the disease have evolved significantly over the years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39621974",
                    "offsetInBeginSection": 1103,
                    "offsetInEndSection": 1287,
                    "text": "Various molecules have been proposed as pain biomarkers for fibromyalgia, including neurotransmitters, neuropeptides, growth factors, and cytokines with possible etiological relevance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39621974",
                    "offsetInBeginSection": 1648,
                    "offsetInEndSection": 1793,
                    "text": "A set of 5 differentially expressed inflammatory genes have been identified as potential biomarkers of a micro-inflammation fibromyalgia subtype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39621974",
                    "offsetInBeginSection": 1794,
                    "offsetInEndSection": 1878,
                    "text": "Proposed triggers of micro-inflammation include bacterial disease and gut dysbiosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the cause of Fibromyalgia?",
            "type": "factoid",
            "id": "6810db0a353a4a2e6b000014",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39741788",
                "http://www.ncbi.nlm.nih.gov/pubmed/39741746",
                "http://www.ncbi.nlm.nih.gov/pubmed/39741501",
                "http://www.ncbi.nlm.nih.gov/pubmed/39740747",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739866",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739382",
                "http://www.ncbi.nlm.nih.gov/pubmed/39738517",
                "http://www.ncbi.nlm.nih.gov/pubmed/39736623",
                "http://www.ncbi.nlm.nih.gov/pubmed/39735600",
                "http://www.ncbi.nlm.nih.gov/pubmed/39735191"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39741788",
                    "offsetInBeginSection": 266,
                    "offsetInEndSection": 444,
                    "text": "radiomics patterns derived from pretreatment computed tomography images in rectal cancer and its relationship with treatment response measurement criteria have been investigated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39741746",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 323,
                    "text": "A machine learning-based approach is presented in this exploratory study for GBM patients' treatment response assessment based on radiomics extracted from magnetic resonance (MR) images.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39741501",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Deep learning-based radiomics techniques have the potential to aid specialists and physicians in performing decision-making in COVID-19 scenarios.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740747",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 342,
                    "text": "To explore the relationship between MRI perfusion metrics (rCBV, rCBF), genetic markers, and contrast enhancement patterns in gliomas, aiming to enhance diagnostic accuracy and inform personalized therapeutic strategies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740747",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 482,
                    "text": "Additionally, other radiological features, such as the T2/FLAIR mismatch sign, are evaluated for their predictive utility in IDH mutations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739866",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 256,
                    "text": "This retrospective study explores two radiomics methods combined with other clinical variables for predicting recurrence free survival (RFS) and overall survival (OS) in patients with pulmonary metastases treated with stereotactic body radiotherapy (SBRT).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739866",
                    "offsetInBeginSection": 364,
                    "offsetInEndSection": 611,
                    "text": "First-order radiomic features were extracted using two methods: 2D CT texture analysis (CTTA) using TexRAD software, and a data-driven technique: functional principal components analysis (FPCA) using segmented tumoral and peri-tumoural 3D regions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739382",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "The study aimed to develop a radiomics model to assess carotid artery plaque vulnerability using computed tomography angiography images.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739382",
                    "offsetInBeginSection": 552,
                    "offsetInEndSection": 644,
                    "text": "Radiomics features were extracted and reduced using the LASSO method to minimize redundancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39738517",
                    "offsetInBeginSection": 1751,
                    "offsetInEndSection": 1857,
                    "text": "Radiomics is a powerful non-invasive tool that could potentially add to visual information obtained on CT.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is radiomics?",
            "type": "summary",
            "id": "680a080b18b1e36f2e00014b",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39683612",
                "http://www.ncbi.nlm.nih.gov/pubmed/39645067",
                "http://www.ncbi.nlm.nih.gov/pubmed/39616355",
                "http://www.ncbi.nlm.nih.gov/pubmed/39560527",
                "http://www.ncbi.nlm.nih.gov/pubmed/39559258",
                "http://www.ncbi.nlm.nih.gov/pubmed/39554395",
                "http://www.ncbi.nlm.nih.gov/pubmed/39553313",
                "http://www.ncbi.nlm.nih.gov/pubmed/39527056",
                "http://www.ncbi.nlm.nih.gov/pubmed/39507912",
                "http://www.ncbi.nlm.nih.gov/pubmed/39507513"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39683612",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 645,
                    "text": "This is a randomized, double-blinded, placebo-controlled trial among 160 Caucasian, postmenopausal women with no current diagnosis of osteoporosis or supplementation with pro- or prebiotics, and no medical treatment affecting bone turnover.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39683612",
                    "offsetInBeginSection": 752,
                    "offsetInEndSection": 994,
                    "text": "The primary outcome is the relative change (%) in total bone mineral density of the distal tibia at 12 months post-treatment between the active and placebo groups, as determined via high-resolution peripheral quantitative computed tomography.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39645067",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 338,
                    "text": "Studies have found that early-life exercise can reduce the risk of fractures and decrease the occurrence of osteoporosis, making it a promising approach for preventing and reversing bone loss.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39645067",
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1511,
                    "text": "Our findings demonstrate that early-life exercise exerts long-term beneficial effects on bone health. All four forms of early-life exercise can delay bone loss due to decreased estrogen and improve the bone microstructure to varying degrees, with resistance and vibration training demonstrating superior protective benefits.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39616355",
                    "offsetInBeginSection": 1282,
                    "offsetInEndSection": 1375,
                    "text": "Research hotspots included bone density, postmenopausal women, vitamin D, hip fractures, etc.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39616355",
                    "offsetInBeginSection": 1376,
                    "offsetInEndSection": 1472,
                    "text": "Research subjects included physical activity, sarcopenia, calcium intake, machine learning, etc.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39560527",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "text": "Bisphosphonates are effective in the treatment of postmenopausal osteoporosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39560527",
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 364,
                    "text": "Denosumab, a human monoclonal antibody, is a widely used antiresorptive agent that is more effective than bisphosphonates in improving bone density.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39560527",
                    "offsetInBeginSection": 1683,
                    "offsetInEndSection": 1877,
                    "text": "Moreover, analyses could not be performed because of high heterogeneity (femoral neck BMD: MD = 3.85, 95% CI = 2.84-4.85, I2 = 97.88%; total hip BMD: MD = 5.65, 95% CI = 4.28-7.02, I2 = 97.91%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39560527",
                    "offsetInBeginSection": 1878,
                    "offsetInEndSection": 2136,
                    "text": "Sequential therapy that involves a transition from bisphosphonates to denosumab had a positive effect on lumbar spine bone density, and this type of therapy may be a potential treatment option for increasing lumbar spine bone density in postmenopausal women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Recommended prevention of osteoporosis in postmenopausal women.",
            "type": "list",
            "id": "67e2cfcf18b1e36f2e00009a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39588374",
                "http://www.ncbi.nlm.nih.gov/pubmed/39533360",
                "http://www.ncbi.nlm.nih.gov/pubmed/39462090",
                "http://www.ncbi.nlm.nih.gov/pubmed/39491858",
                "http://www.ncbi.nlm.nih.gov/pubmed/39460829",
                "http://www.ncbi.nlm.nih.gov/pubmed/39684758",
                "http://www.ncbi.nlm.nih.gov/pubmed/39475521",
                "http://www.ncbi.nlm.nih.gov/pubmed/39732622"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39588374",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "In teleosts, the immunoglobulin classes produced by B cells are IgM, IgD, and IgT/IgZ.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39533360",
                    "offsetInBeginSection": 385,
                    "offsetInEndSection": 615,
                    "text": "Here, we analyzed IgA, IgE and IgG responses to gut bacteria in subjects with either IgE or non-IgE mediated CMA to identify relative proportions of Ig-coated bacteria and characterize unique disease specific microbial signatures.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39533360",
                    "offsetInBeginSection": 616,
                    "offsetInEndSection": 737,
                    "text": "Multi-parametric flow cytometry analysis was used to identify IgA, IgE and IgG responses to gut bacteria in CMA patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39462090",
                    "offsetInBeginSection": 342,
                    "offsetInEndSection": 528,
                    "text": "Here, we quantified the protein levels of IgA, IgM, IgG and albumin in serum and cerebrospinal fluid (CSF) samples of 80 MS patients and 28 neurological controls to calculate Ig indices.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39491858",
                    "offsetInBeginSection": 1212,
                    "offsetInEndSection": 1446,
                    "text": " Microbiota SCFAs were found to lower both overall and antigen-specific IgE levels, indicating their potential to mitigate IgE-related allergic reactions, much like their effect on class-switch recombination (CSR) towards IgG and IgA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39533360",
                    "offsetInBeginSection": 1342,
                    "offsetInEndSection": 1463,
                    "text": "Alpha and beta diversities displayed significant differences in IgA-, IgE-, and IgG-coated bacteria in AD and ENP groups.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39462090",
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 581,
                    "text": "In addition, we quantified presence of meningeal IgA",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39460829",
                    "offsetInBeginSection": 1414,
                    "offsetInEndSection": 1553,
                    "text": "FCER1G (Fc Fragment of IgE Receptor Ig) was identified as the common regulator in activating the anti-tumor immune response at both stages.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39684758",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "The development of rapid analysis of human serum for the presence of allergen-specific Immunoglobulin E (IgE) is currently important.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39475521",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 443,
                    "text": "Human milk contained more immunoglobulins involved in the adaptive immune response, playing a crucial role in mucosal defense in newborn babies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the major classes of immunoglobulins?",
            "type": "list",
            "id": "680fcb72353a4a2e6b00000e",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38632951",
                "http://www.ncbi.nlm.nih.gov/pubmed/39541652",
                "http://www.ncbi.nlm.nih.gov/pubmed/38375145",
                "http://www.ncbi.nlm.nih.gov/pubmed/38447810",
                "http://www.ncbi.nlm.nih.gov/pubmed/38421771",
                "http://www.ncbi.nlm.nih.gov/pubmed/38871800",
                "http://www.ncbi.nlm.nih.gov/pubmed/39310185",
                "http://www.ncbi.nlm.nih.gov/pubmed/38814564",
                "http://www.ncbi.nlm.nih.gov/pubmed/38462952",
                "http://www.ncbi.nlm.nih.gov/pubmed/39534879"
                ],
            "snippets": [
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/38632951",
                "offsetInBeginSection": 855,
                "offsetInEndSection": 1007,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "We evaluated TMBstable using both simulated and real non-small cell lung cancer and nasopharyngeal carcinoma samples, comparing it with advanced callers"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/39541652",
                "offsetInBeginSection": 979,
                "offsetInEndSection": 1039,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "However, only 16 of these patients received epilepsy surgery"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/38375145",
                "offsetInBeginSection": 177,
                "offsetInEndSection": 266,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": ", on metabolism and tissue structure) to clinical examination for surgical guidance [1,2]"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/38447810",
                "offsetInBeginSection": 0,
                "offsetInEndSection": 107,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "Endoscopic biliary stent insertion has been widely used for the treatment of benign biliary stricture (BBS)"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/38421771",
                "offsetInBeginSection": 1423,
                "offsetInEndSection": 1669,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "We further propose a collection of JSON schemas (LocareJSON) for specifying geometric objects by atlas coordinates, suitable as a starting point for co-visualization of different data in an anatomical context and for enabling spatial data queries"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/38871800",
                "offsetInBeginSection": 521,
                "offsetInEndSection": 704,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "Every image in the CSXA is enriched with gender, age, pixel equivalent, asymptomatic and symptomatic classifications, cervical curvature categorization and 118 quantitative parameters"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/39310185",
                "offsetInBeginSection": 150,
                "offsetInEndSection": 361,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "For the modeling of thermodynamic properties, statistical associating fluid theory (SAFT)-based equations of state, such as perturbed-chain polar (PCP)-SAFT, have been proven powerful and found broad application"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/38814564",
                "offsetInBeginSection": 747,
                "offsetInEndSection": 895,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "Among the 120 PET tracers, compound structures with chemical and physical properties were obtained from the PubChem website or the ChemDraw software"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/38462952",
                "offsetInBeginSection": 1699,
                "offsetInEndSection": 1836,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "Example results for Siemens and GE scanners are shown, including side-by-side comparisons for protocols with similar clinical indications"
                },
                {
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/39534879",
                "offsetInBeginSection": 567,
                "offsetInEndSection": 634,
                "beginSection": "abstract",
                "endSection": "abstract",
                "text": "To address this challenge, the EIFFEL ontology (EIFF-O) is proposed"
                }
            ],
            "body": "Is Laparoscopic salpingectomy used to treat testicular cancer?",
            "type": "yesno",
            "id": "6810ff8f353a4a2e6b000017",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38807147",
                "http://www.ncbi.nlm.nih.gov/pubmed/34687924"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38807147",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 359,
                    "text": "all three types of VL device (Macintosh-style, hyper-angulated and channeled) reduced the risk of failed intubation and increased the likelihood of first-pass success.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34687924",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 624,
                    "text": "There were four types of video-stylets and three types of video-laryngoscopes examined.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please list the types of Videolaryngoscopy for adults undergoing tracheal intubation",
            "type": "list",
            "id": "67f8527318b1e36f2e000104",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39725239",
                "http://www.ncbi.nlm.nih.gov/pubmed/39733853",
                "http://www.ncbi.nlm.nih.gov/pubmed/39733822",
                "http://www.ncbi.nlm.nih.gov/pubmed/39693001",
                "http://www.ncbi.nlm.nih.gov/pubmed/39691422",
                "http://www.ncbi.nlm.nih.gov/pubmed/39688562",
                "http://www.ncbi.nlm.nih.gov/pubmed/39678258",
                "http://www.ncbi.nlm.nih.gov/pubmed/39665188",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739680",
                "http://www.ncbi.nlm.nih.gov/pubmed/39734024"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725239",
                    "offsetInBeginSection": 785,
                    "offsetInEndSection": 1071,
                    "text": "The most prevalent kind of glial cells in the central nervous system are called astrocytes. They have a unique significance in cerebral function because of their wide range of functions in maintaining homeostasis in the central nervous system, regulating synaptic plasticity, and so on.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39733853",
                    "offsetInBeginSection": 485,
                    "offsetInEndSection": 735,
                    "text": "In the early stage of ischemia, reactive astrocytes proliferate moderately and surround the ischemic tissue to prevent the spread of the lesion. At the same time, reactive astrocytes release neuroprotective factors, ultimately relieving brain injury.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39733853",
                    "offsetInBeginSection": 736,
                    "offsetInEndSection": 1041,
                    "text": "In the late stage of ischemia, reactive astrocytes excessively proliferate and migrate to form dense glial scar tissue, which hinders the repair of damaged tissue. At the same time, reactive astrocytes in the glial scar release a large number of neurotoxic factors, ultimately aggravating ischemic stroke.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39733853",
                    "offsetInBeginSection": 83,
                    "offsetInEndSection": 395,
                    "text": "Astrocytes, as the most abundant type of glial cells in the central nervous system, are activated into reactive astrocytes after cerebral ischemia, and this process involves the activation or change of a series of cell surface receptors, ion channels and ion transporters, GTPases, signaling pathways, and so on.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39733822",
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 897,
                    "text": "significant changes have been observed at the capillary level, including alterations in iron transport, vasculogenesis, astrocyte endfeet, and pericytes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39693001",
                    "offsetInBeginSection": 247,
                    "offsetInEndSection": 411,
                    "text": "Astrocytes, which are the predominant glial cells in the central nervous system (CNS), release significant amounts of proinflammatory cytokines upon overactivation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39691422",
                    "offsetInBeginSection": 197,
                    "offsetInEndSection": 487,
                    "text": "The primary immune cells within the CNS include microglia, astrocytes, T cells, and B cells. They work together, continuously monitor the CNS environment for signs of infection, injury, or disease, and respond by phagocytosing debris, releasing cytokines, and recruiting other immune cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39688562",
                    "offsetInBeginSection": 685,
                    "offsetInEndSection": 990,
                    "text": "Astrocytes are the only brain resident cells that have ammonia-metabolizing machinery and are therefore putatively most susceptible to ammonia elevation. Based on a large body of mostly in vitro evidence, ammonia-induced cellular and molecular disturbances include astrocyte swelling and oxidative stress.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39678258",
                    "offsetInBeginSection": 326,
                    "offsetInEndSection": 426,
                    "text": "They allow the passage of small molecules (<1.5 kDa) between the cytoplasm and extracellular matrix.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39665188",
                    "offsetInBeginSection": 709,
                    "offsetInEndSection": 818,
                    "text": "BBB is formed by the combination of cerebral endothelial cells, astrocytes, neurons, pericytes and microglia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the functions of astrocytes in the CNS?",
            "type": "summary",
            "id": "680a081d18b1e36f2e00014c",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39353298",
                "http://www.ncbi.nlm.nih.gov/pubmed/38952208",
                "http://www.ncbi.nlm.nih.gov/pubmed/39624012",
                "http://www.ncbi.nlm.nih.gov/pubmed/39185700"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39353298",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 420,
                    "text": "Glioblastoma (GBM) is the most common and lethal brain tumor, characterized by an immunosuppressive TME, with restricted immune cell infiltration.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38952208",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 323,
                    "text": "Nevertheless, the immune privilege phenomenon, coupled with the generally low immunogenicity of vaccines, frequently hampers the presence of lymphocytes within brain tumors, particularly in brain tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39624012",
                    "offsetInBeginSection": 1027,
                    "offsetInEndSection": 1234,
                    "text": "Notably, in liver hepatocellular carcinoma, glioblastoma multiforme, low-grade gliomas, and acute myeloid leukemia, MKNK2 expression shows a strong correlation with clinical outcomes and immune infiltration.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38952208",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Immunotherapy can potentially suppress the highly aggressive glioblastoma (GBM) by promoting T lymphocyte infiltration.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39185700",
                    "offsetInBeginSection": 521,
                    "offsetInEndSection": 623,
                    "text": "mesenchymal-subtype tumors being associated with increased immune cell infiltration and worse outcome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do glioblastoma tumors have a high degree of lymphocyte infiltration?",
            "type": "yesno",
            "id": "67fc20ee18b1e36f2e00012a",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39508953",
                "http://www.ncbi.nlm.nih.gov/pubmed/39564064",
                "http://www.ncbi.nlm.nih.gov/pubmed/39398392",
                "http://www.ncbi.nlm.nih.gov/pubmed/39398391",
                "http://www.ncbi.nlm.nih.gov/pubmed/38885606",
                "http://www.ncbi.nlm.nih.gov/pubmed/38665763",
                "http://www.ncbi.nlm.nih.gov/pubmed/38255425",
                "http://www.ncbi.nlm.nih.gov/pubmed/37620664",
                "http://www.ncbi.nlm.nih.gov/pubmed/37438480",
                "http://www.ncbi.nlm.nih.gov/pubmed/37326320"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39508953",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "text": "Nissen fundoplication (NF) is a common surgical procedure to treat gastroesophageal reflux disease; however, a subset of patients may continue to experience symptoms or develop symptom recurrence despite a successful procedure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39564064",
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 536,
                    "text": "Laparoscopic Nissen fundoplication is often considered the standard for treating gastroesophageal reflux disease-related HH due to its effectiveness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39398392",
                    "offsetInBeginSection": 221,
                    "offsetInEndSection": 383,
                    "text": "Laparoscopic Nissen fundoplication (LNF) still is considered as gold standard, but alternative procedures have been developed and evaluated within the past years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39398391",
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 573,
                    "text": "For 70 years, the 360 Nissen fundoplication has dominated the surgical scenario and is still considered the gold-standard treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38885606",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Laparoscopic Nissen Fundoplication is an effective standard surgical procedure for treatment of severe GERD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38665763",
                    "offsetInBeginSection": 1089,
                    "offsetInEndSection": 1164,
                    "text": "Laparoscopic Nissen fundoplication was the most common procedure performed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38255425",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "text": "Nissen Fundoplication (NF) is a frequently performed procedure in children.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37620664",
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 289,
                    "text": "Laparoscopic fundoplication is the surgical procedure of choice for treatment of GERD; however, there remains a debate on the exact mechanism through which it prevents reflux.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37438480",
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 423,
                    "text": "Laparoscopic Nissen fundoplication has historically been the anti-reflux procedure of choice, but the procedure is associated with discernable rates of postoperative dysphagia and gas-bloat syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37326320",
                    "offsetInBeginSection": 1205,
                    "offsetInEndSection": 1405,
                    "text": "Collis gastroplasty combined with Nissen fundoplication provides low hernia recurrence, good control of symptoms, and improved quality of life in patients with large hiatal hernia and short esophagus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is Nissen fundoplication",
            "type": "factoid",
            "id": "67fc1a3818b1e36f2e000129",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39351778",
                "http://www.ncbi.nlm.nih.gov/pubmed/39227579",
                "http://www.ncbi.nlm.nih.gov/pubmed/39433199",
                "http://www.ncbi.nlm.nih.gov/pubmed/39506344",
                "http://www.ncbi.nlm.nih.gov/pubmed/39662629",
                "http://www.ncbi.nlm.nih.gov/pubmed/39113198",
                "http://www.ncbi.nlm.nih.gov/pubmed/39119483",
                "http://www.ncbi.nlm.nih.gov/pubmed/39157281",
                "http://www.ncbi.nlm.nih.gov/pubmed/39673521",
                "http://www.ncbi.nlm.nih.gov/pubmed/39624818"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39351778",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Turner syndrome (TS) is characterized by a partial or complete absence of the second X chromosome in female individuals.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39227579",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Turner syndrome (TS) is a genetic condition characterized by partial or complete monosomy X.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39433199",
                    "offsetInBeginSection": 390,
                    "offsetInEndSection": 552,
                    "text": "Of the 28 girls, 21 had a 45,X/46,XX mosaic karyotype; 5 had structural aberrations of the X chromosome; 1 had a 45,X monosomy; and 1 had a 45,X/47,XXX karyotype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39506344",
                    "offsetInBeginSection": 401,
                    "offsetInEndSection": 608,
                    "text": " Data for 4 groups of subjects were obtained as follows: monosomy X (n=56); X structural abnormality (n=26); X mosaicism without structural abnormality (n=41); X mosaicism with structural abnormality (n=71).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39662629",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 792,
                    "text": "56% with 45X karyotype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39113198",
                    "offsetInBeginSection": 763,
                    "offsetInEndSection": 841,
                    "text": "67.6 % (n=96) of total patients with TS and LD had non-mosaic 45, X karyotype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39351778",
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 279,
                    "text": "Here, patients with Xp deletion involving SHOX haploinsufficiency caused by unbalanced X-autosome translocations were discussed and considered as TS variants.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39351778",
                    "offsetInBeginSection": 1471,
                    "offsetInEndSection": 1584,
                    "text": "The patients with Xp deletion caused by unbalanced X-autosome translocations should be considered as TS variants.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39119483",
                    "offsetInBeginSection": 556,
                    "offsetInEndSection": 608,
                    "text": "The genetic karyotype identified was 46,X,i(X)(q10).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39157281",
                    "offsetInBeginSection": 437,
                    "offsetInEndSection": 515,
                    "text": "Karyotyping revealed a mosaic karyotype of 45,X[44]/46,XY[5]/46,X,idic(Yp)[1].",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the genetic variants in Turner syndrome?",
            "type": "factoid",
            "id": "67e285b018b1e36f2e00007b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39740604",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739468",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739263",
                "http://www.ncbi.nlm.nih.gov/pubmed/39734356",
                "http://www.ncbi.nlm.nih.gov/pubmed/39723481",
                "http://www.ncbi.nlm.nih.gov/pubmed/39721719",
                "http://www.ncbi.nlm.nih.gov/pubmed/39719526",
                "http://www.ncbi.nlm.nih.gov/pubmed/39718734",
                "http://www.ncbi.nlm.nih.gov/pubmed/39706815",
                "http://www.ncbi.nlm.nih.gov/pubmed/39704391"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740604",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "This study aimed to evaluate the prognostic outcomes of thyroidectomy extent in unilateral TNM T1 or T2 papillary thyroid carcinoma with lateral lymph node metastasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739468",
                    "offsetInBeginSection": 716,
                    "offsetInEndSection": 890,
                    "text": "Malignant neoplasm accounted 12 in 100 cases of multi-nodular goiter. Among them 7.0% were Papillary thyroid carcinoma (PTC) and 5.0% were Follicular thyroid carcinoma (FTC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739468",
                    "offsetInBeginSection": 951,
                    "offsetInEndSection": 1066,
                    "text": "Age of the patients and duration of multi-nodularity found statistically significant for development of malignancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739263",
                    "offsetInBeginSection": 432,
                    "offsetInEndSection": 625,
                    "text": "All consecutive adult patients who underwent total thyroidectomy in one step (TT1 group) or two steps (TT2 group) for follicular, oncocytic, or papillary TC between 2000 and 2020 were included.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739263",
                    "offsetInBeginSection": 903,
                    "offsetInEndSection": 1047,
                    "text": "Following adjustment, TT2 patients had significantly lower rates of transient hypocalcemia than TT1 patients did (3.2% versus 13.8%, p < 0.001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734356",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "To investigate the association between the rs2267437, rs5751129 and rs132770 polymorphisms of the",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734356",
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 479,
                    "text": "In the rs2267437 polymorphism, individuals with the GG genotype had lower risk of PTC than those with the wild-type CC genotype (p = 0.037, 95% CI: 0.19-0.96, OR: 0.67).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734356",
                    "offsetInBeginSection": 480,
                    "offsetInEndSection": 664,
                    "text": "The combined genotypes CG+GG were related to a reduced risk of PTC compared to the wild-type CC genotype (p = 0.023, 95% CI: 0.40-0.94, OR: 0.61) in the recessive model (GC+GG vs. CC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734356",
                    "offsetInBeginSection": 809,
                    "offsetInEndSection": 928,
                    "text": "This study demonstrated that rs2267437 polymorphism may have a protective effect against PTC in the Turkish population.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734356",
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 1016,
                    "text": "However, the rs5751129 and rs132770 polymorphisms were not associated with the disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Factors that are associated with thyroid cancer.",
            "type": "list",
            "id": "67fbe21818b1e36f2e000113",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39082958",
                "http://www.ncbi.nlm.nih.gov/pubmed/39015733",
                "http://www.ncbi.nlm.nih.gov/pubmed/38924472",
                "http://www.ncbi.nlm.nih.gov/pubmed/38769254",
                "http://www.ncbi.nlm.nih.gov/pubmed/38763413",
                "http://www.ncbi.nlm.nih.gov/pubmed/38752751",
                "http://www.ncbi.nlm.nih.gov/pubmed/38002487",
                "http://www.ncbi.nlm.nih.gov/pubmed/37388544",
                "http://www.ncbi.nlm.nih.gov/pubmed/37279626",
                "http://www.ncbi.nlm.nih.gov/pubmed/37276802"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39082958",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "Treatment of Catatonia With Electroconvulsive Therapy in a Patient With Neuropsychiatric Systemic Lupus Erythematosus, Epilepsy, and Cerebral Palsy.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39015733",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 335,
                    "text": "Electroconvulsive therapy (ECT) is widely recognized as one of the most effective treatments for various psychiatric disorders and is generally considered safe. However, a few reports have mentioned that multiple ECT sessions could induce electroencephalography (EEG) abnormalities and epileptic seizures, a serious side effect of ECT.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38924472",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "Electroconvulsive Therapy as an Effective and Safe Treatment in a Pregnant Patient With Thrombophilia and Epilepsy.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38769254",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Electroconvulsive therapy (ECT) has been suggested as a treatment option for refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38763413",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Electroconvulsive therapy in new onset refractory status epilepticus (NORSE) in a pediatric patient.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38752751",
                    "offsetInBeginSection": 758,
                    "offsetInEndSection": 907,
                    "text": "Moreover, this case is unique given our patient's later age of symptom onset and given that her symptoms responded well to electroconvulsive therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38002487",
                    "offsetInBeginSection": 627,
                    "offsetInEndSection": 716,
                    "text": "including electroconvulsive therapy, vagus nerve stimulation, and deep brain stimulation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37388544",
                    "offsetInBeginSection": 919,
                    "offsetInEndSection": 1088,
                    "text": "Ten had electroconvulsive therapy (ECT), seven had vagal nerve stimulation (VNS), and four had deep brain stimulation (DBS); one patient had initially VNS and later DBS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37279626",
                    "offsetInBeginSection": 1202,
                    "offsetInEndSection": 1409,
                    "text": "Non-pharmacological therapies such as ketogenic diet, electroconvulsive therapy, and therapeutic hypothermia were not available in most district and tertiary hospitals for refractory and super-refractory SE.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37276802",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 251,
                    "text": "Clinicians have treated super refractory status epilepticus (SRSE) with electroconvulsive therapy (ECT); however, data supporting the practice are scant and lack rigorous evaluation of continuous electroencephalogram (cEEG) changes related to therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Electroconvulsive Therapy used for any type of epilepsy?",
            "type": "yesno",
            "id": "680f4ae9353a4a2e6b000009",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39742261",
                "http://www.ncbi.nlm.nih.gov/pubmed/39740502",
                "http://www.ncbi.nlm.nih.gov/pubmed/39697346",
                "http://www.ncbi.nlm.nih.gov/pubmed/39693782",
                "http://www.ncbi.nlm.nih.gov/pubmed/39684827",
                "http://www.ncbi.nlm.nih.gov/pubmed/39678138",
                "http://www.ncbi.nlm.nih.gov/pubmed/39672019",
                "http://www.ncbi.nlm.nih.gov/pubmed/39644208",
                "http://www.ncbi.nlm.nih.gov/pubmed/39612105",
                "http://www.ncbi.nlm.nih.gov/pubmed/39609464"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39742261",
                    "offsetInBeginSection": 896,
                    "offsetInEndSection": 1015,
                    "text": "miR-27a-3p contributed to the proliferation and migration of hepatoma cells and promoted M2 polarization of macrophage.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39742261",
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1179,
                    "text": "HSC-sEVs overexpressing miR-27a-3p can directly facilitate tumor progression and modulate macrophage polarization, indirectly contributing to hepatoma progression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740502",
                    "offsetInBeginSection": 1382,
                    "offsetInEndSection": 1561,
                    "text": "Silencing HSPA5 alleviated glioma hypoxia tolerance and induced the polarization of TAMs toward the M1 phenotype. The induced macrophages could exhibit a tumor-suppressive effect.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39697346",
                    "offsetInBeginSection": 787,
                    "offsetInEndSection": 1013,
                    "text": "Single-cell sequencing data and immunohistochemistry revealed abundant immunosuppressive tumor-associated macrophages in lung metastases. Patients with high M2 macrophage infiltration had shorter lung metastasis-free survival.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39693782",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "text": "Tumor-associated macrophages (TAMs) contribute to tumor progression by promoting angiogenesis, remodeling the tumor extracellular matrix, inducing tumor invasion and metastasis, as well as immune evasion.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39693782",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 432,
                    "text": "Due to the high plasticity of TAMs, they can polarize into different phenotypes with distinct functions, which are primarily categorized as the pro-inflammatory, anti-tumor M1 type, and the anti-inflammatory, pro-tumor M2 type.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39693782",
                    "offsetInBeginSection": 433,
                    "offsetInEndSection": 580,
                    "text": "Notably, anti-tumor macrophages not only directly phagocytize tumor cells, but also present tumor-specific antigens and activate adaptive immunity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39684827",
                    "offsetInBeginSection": 470,
                    "offsetInEndSection": 542,
                    "text": "co-culture of M0 and M2 macrophages promoted WM cell growth and survival",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39684827",
                    "offsetInBeginSection": 631,
                    "offsetInEndSection": 685,
                    "text": "GLI3 expression was induced in M2 macrophages (not M1)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39678138",
                    "offsetInBeginSection": 311,
                    "offsetInEndSection": 452,
                    "text": "Tumour-associated macrophages (TAMs) are an important component of the tumour microenvironment and play a crucial role in cancer progression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the characteristics of the M1/M2 macrophage polarization paradigm in the tumor microenvironment?",
            "type": "summary",
            "id": "67fd922518b1e36f2e000143",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38910425",
                "http://www.ncbi.nlm.nih.gov/pubmed/39506109",
                "http://www.ncbi.nlm.nih.gov/pubmed/38398707",
                "http://www.ncbi.nlm.nih.gov/pubmed/38335010",
                "http://www.ncbi.nlm.nih.gov/pubmed/39730291",
                "http://www.ncbi.nlm.nih.gov/pubmed/39631469",
                "http://www.ncbi.nlm.nih.gov/pubmed/39707073",
                "http://www.ncbi.nlm.nih.gov/pubmed/38654312",
                "http://www.ncbi.nlm.nih.gov/pubmed/38391929",
                "http://www.ncbi.nlm.nih.gov/pubmed/39550509"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38910425",
                    "offsetInBeginSection": 873,
                    "offsetInEndSection": 971,
                    "text": "The mitochondria in a cell are generally accepted as the authority with respect to ATP production.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39506109",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "Mitochondria serve a crucial role in cell growth and proliferation by supporting both ATP synthesis and the production of macromolecular precursors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38398707",
                    "offsetInBeginSection": 531,
                    "offsetInEndSection": 629,
                    "text": "Mitochondria are an essential organelle involved in cellular bioenergetics and signaling pathways.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38335010",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "Mitochondria are perhaps best known as the \"powerhouse of the cell\" for their role in ATP production required for numerous cellular activities.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730291",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 360,
                    "text": "Mitochondrial dysfunction is an important driver of neurodegeneration and synaptic abnormalities in Alzheimer's disease (AD). Amyloid beta (A) in mitochondria leads to increased reactive oxygen species (ROS) production, resulting in a vicious cycle of oxidative stress in coordination with a defective electron transport chain (ETC), decreasing ATP production.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39631469",
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 890,
                    "text": "Mitochondrial membrane potential (MMP), ATP production, ROS production, and Mitotracker Red mitochondrial morphology were assayed to assess mitochondrial function.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39707073",
                    "offsetInBeginSection": 798,
                    "offsetInEndSection": 976,
                    "text": "This enhanced contractile capacity of heart was benefited from mitochondrial protection reflected by ultrastructure improvement, augment in mitochondrial mass and ATP production.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38654312",
                    "offsetInBeginSection": 908,
                    "offsetInEndSection": 1022,
                    "text": "loss of AMPK activity induced abnormal distribution, reduced ATP production and mtDNA copy number of mitochondria.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38391929",
                    "offsetInBeginSection": 1031,
                    "offsetInEndSection": 1163,
                    "text": "resulting in a fragmented mitochondrial network and reduced bioenergetic function, including decreased mitochondrial ATP production,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730291",
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 582,
                    "text": "AD neurons exhibit impaired mitochondrial dynamics, evidenced by fusion and fission imbalances, increased fragmentation, and deficient mitochondrial biogenesis, contributing to fewer mitochondria in brains of AD patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What organelle is responsible for ATP production?",
            "type": "factoid",
            "id": "680a07f918b1e36f2e00014a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39739489",
                "http://www.ncbi.nlm.nih.gov/pubmed/39734449",
                "http://www.ncbi.nlm.nih.gov/pubmed/39733605",
                "http://www.ncbi.nlm.nih.gov/pubmed/39717503",
                "http://www.ncbi.nlm.nih.gov/pubmed/39687604",
                "http://www.ncbi.nlm.nih.gov/pubmed/39676020",
                "http://www.ncbi.nlm.nih.gov/pubmed/39648320",
                "http://www.ncbi.nlm.nih.gov/pubmed/39616074",
                "http://www.ncbi.nlm.nih.gov/pubmed/39528247",
                "http://www.ncbi.nlm.nih.gov/pubmed/39525756"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739489",
                    "offsetInBeginSection": 630,
                    "offsetInEndSection": 1201,
                    "text": "Infants who developed jaundice before three months of age, had direct bilirubin of more than 20.0% of the total bilirubin if total bilirubin is 5 mg/dl or more than 1.0 mg/dl if total bilirubin is <5 mg/dl, with pale stool and dark urine were included as cases while infants who visited hospital with a diagnosis of acute bronchiolitis, reactive airway disease and acute viral infection but no evidence of liver, gastrointestinal disease or renal disease checked by means of medical history, physical examination and a review of medical records were included as controls.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734449",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "The Kasai procedure (KPE) is an important treatment for biliary atresia (BA), the most common cause of neonatal obstructive jaundice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39733605",
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 614,
                    "text": "Infants diagnosed with BA exhibited significantly elevated levels of plasma pIgR autoantibodies, which positively correlated with hepatic inflammation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39717503",
                    "offsetInBeginSection": 1068,
                    "offsetInEndSection": 1190,
                    "text": "EFEMP1 was found via a genome-wide association study to be a susceptibility gene for the neonatal disease biliary atresia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39687604",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "Biliary atresia is a fibrosing cholangiopathy affecting neonates that is thought to result from a prenatal environmental insult to the bile duct.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39687604",
                    "offsetInBeginSection": 660,
                    "offsetInEndSection": 875,
                    "text": "We used primary extrahepatic cholangiocyte spheroids and extrahepatic bile duct explants from both neonatal [a total of 86 postnatal day (P) 2 mouse pups and 18 P2 rat pups (n = 8-10 per condition for both species)]",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39687604",
                    "offsetInBeginSection": 1264,
                    "offsetInEndSection": 1340,
                    "text": "We identified MC-RR as a selective neonatal extrahepatic cholangiocyte toxin",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39676020",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 63,
                    "text": "A rare case of neonatal coexisting jejunal and biliary atresia.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39648320",
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 325,
                    "text": "Infants born from 2010 to 2021, who underwent HS <6 months postpartum for BA, were included and data sourced from electronic medical records.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39616074",
                    "offsetInBeginSection": 642,
                    "offsetInEndSection": 783,
                    "text": "The median age of the infants was 157 days, with 37 boys (57.8%) and 27 girls (42.2%). Biliary atresia was the most common diagnosis (85.9%),",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What age group is commonly affected by biliary atresia?",
            "type": "factoid",
            "id": "67cdc78381b102733300001a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39735391",
                "http://www.ncbi.nlm.nih.gov/pubmed/39727645",
                "http://www.ncbi.nlm.nih.gov/pubmed/39673511",
                "http://www.ncbi.nlm.nih.gov/pubmed/39665304",
                "http://www.ncbi.nlm.nih.gov/pubmed/39594225",
                "http://www.ncbi.nlm.nih.gov/pubmed/39584667",
                "http://www.ncbi.nlm.nih.gov/pubmed/39539767",
                "http://www.ncbi.nlm.nih.gov/pubmed/39512358",
                "http://www.ncbi.nlm.nih.gov/pubmed/39499311",
                "http://www.ncbi.nlm.nih.gov/pubmed/39478946"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39735391",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 343,
                    "text": "Celiac disease is an autoimmune condition that affects approximately 1% of the worldwide community. Originally thought to be confined mostly to the small intestine, resulting in villous atrophy and nutrient malabsorption, it has more recently been implicated in systemic manifestations as well, particularly when undiagnosed or left untreated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39727645",
                    "offsetInBeginSection": 1140,
                    "offsetInEndSection": 1496,
                    "text": "Significant differences in clinical manifestations, histological findings, and treatment outcomes were observed. Notably, weight loss, nutritional deficiencies and electrolyte abnormalities were more commonly associated with ICI-induced celiac disease. Regarding pathology, duodenal villous blunting was noted more commonly with ICI-induced celiac disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39673511",
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 325,
                    "text": "CD manifests with heterogeneous array of symptoms, including a wide range of intestinal and extraintestinal symptoms and manifestations (EIMs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39665304",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 203,
                    "text": "Anecdotal reports describe patients with concurrent idiopathic inflammatory myopathy (IIM) and celiac disease (CeD) in whom the introduction of a gluten-free diet led to dramatic improvement of myositis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39665304",
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 459,
                    "text": "The collected evidence was suggestive of associations between myositis disease activity and gluten exposure in some patients with IIM-CeD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39665304",
                    "offsetInBeginSection": 933,
                    "offsetInEndSection": 1189,
                    "text": "Common traits include shared genetic predisposition through HLA-DQ2.5/-DQ8, disease activity-associated autoantibodies, histopathological parallels with inflammatory cell infiltrates, and similarly distributed structural homologous transglutaminases (TGs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39665304",
                    "offsetInBeginSection": 1190,
                    "offsetInEndSection": 1319,
                    "text": "HLA-DQ2.5-restricted gluten-specific CD4+ T cells of a rare, uniform phenotype are reported in CeD and connective tissue disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39594225",
                    "offsetInBeginSection": 140,
                    "offsetInEndSection": 314,
                    "text": "In addition to gastrointestinal manifestations, CD also presents with a variety of extraintestinal symptoms, including significant neurological and neuropsychiatric symptoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39584667",
                    "offsetInBeginSection": 1209,
                    "offsetInEndSection": 1438,
                    "text": "Abdominal pain (42%), bloating (39%), and flatulence (38%) were the most common gastrointestinal symptoms, while 34% of FDRs with CeD were asymptomatic. In addition, pallor was the most frequent nongastrointestinal symptom (54%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39539767",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 73,
                    "text": "Neurologic manifestations may be presenting signs of celiac disease (CD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Manifestations of gluten allergy/intolerance.",
            "type": "list",
            "id": "67d7ff2c18b1e36f2e000049",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36209092",
                "http://www.ncbi.nlm.nih.gov/pubmed/37920490",
                "http://www.ncbi.nlm.nih.gov/pubmed/39318997",
                "http://www.ncbi.nlm.nih.gov/pubmed/37108633",
                "http://www.ncbi.nlm.nih.gov/pubmed/37622115"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36209092",
                    "offsetInBeginSection": 890,
                    "offsetInEndSection": 1175,
                    "text": "Six leukocyte types (CD4 memory resting T cells, M0 macrophages, plasma cells, CD8 T cells, CD4 memory activated T cells, and monocytes) were present with a proportion higher than 0.05, i.e. 5%. These six cell types were present in most brain regions with only insignificant variation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37920490",
                    "offsetInBeginSection": 1497,
                    "offsetInEndSection": 1692,
                    "text": "Six most abundant (>5 % of the total population) cell types were observed to be CD4 memory resting T cells, M0 macrophages, plasma cells, CD8 T cells, CD4 memory activated T cells, and monocytes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39318997",
                    "offsetInBeginSection": 901,
                    "offsetInEndSection": 1074,
                    "text": "A total of 17,242 cells were obtained in this study, including 7,224 cells from CSF and 10,018 cells from PB, mainly identified as monocytes, T cells, B cells, and NK cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39318997",
                    "offsetInBeginSection": 403,
                    "offsetInEndSection": 652,
                    "text": "Mononuclear cells from the CSF and PB samples were sequenced using 10x Genomics scRNA-seq. Additionally, scRNA-seq data for CSF from eight healthy individuals were obtained from the Gene Expression Omnibus database, serving as healthy controls (HC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37108633",
                    "offsetInBeginSection": 761,
                    "offsetInEndSection": 1112,
                    "text": "Astrocytes, by modulating exosome cargo, impacts the release of IFN-, IL-17A and CCL2 in our experimental conditions. Considering the proteins concentration in cell culture supernatants and the cellular percentage of Th phenotypes, it could be stated that human astrocytes, by the release of exosomes, are able to modify the activity of human T cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do T cells enter the CNS in healthy individuals?",
            "type": "yesno",
            "id": "680a084018b1e36f2e00014e",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39714278",
                "http://www.ncbi.nlm.nih.gov/pubmed/39689015",
                "http://www.ncbi.nlm.nih.gov/pubmed/39502646",
                "http://www.ncbi.nlm.nih.gov/pubmed/39446669"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39714278",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "Evolving technology and the development of new devices that can aerosolize water present a risk for new sources of Legionella bacteria growth and spread within industrial settings.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39714278",
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 604,
                    "text": "Legionella pneumophila was isolated from 3 devices: 2 water jet cutters and 1 floor scrubber.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39714278",
                    "offsetInBeginSection": 605,
                    "offsetInEndSection": 768,
                    "text": "L. pneumophila sequence type 36 was identified in environmental isolates and 1 patient specimen, indicating that those devices were the likely source of infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39689015",
                    "offsetInBeginSection": 1239,
                    "offsetInEndSection": 1589,
                    "text": "Our findings of a 2- and 3-day lag between rainfall and the date of estimated exposure is consistent with an indirect link with rainfall, rather than a same-day exposure. Potential pathways that can indirectly link rainfall to LD cases include rainfall-mediated declines in public water supplies but greater environmental sampling research is needed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39502646",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "Legionnaires' disease (LD) is a serious type of pneumonia, typically contracted by susceptible people through the inhalation of aerosols contaminated with",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39446669",
                    "offsetInBeginSection": 449,
                    "offsetInEndSection": 643,
                    "text": "Epidemiologic data collected from patient interviews and environmental assessment and sampling results identified private hot tubs on selected cabin balconies as the most likely exposure source.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39446669",
                    "offsetInBeginSection": 876,
                    "offsetInEndSection": 1017,
                    "text": "Hot tubs offer favorable conditions for Legionella growth and transmission when maintained and operated inadequately, regardless of location.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "How do you acquire Legionella pneumophila?",
            "type": "summary",
            "id": "67e2b80618b1e36f2e00008f",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38418952",
                "http://www.ncbi.nlm.nih.gov/pubmed/32361702"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38418952",
                    "offsetInBeginSection": 392,
                    "offsetInEndSection": 477,
                    "text": "The hiccups resolved gradually after antibiotic treatment and surgical decortication.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Has Antibiotic use induced hiccups?",
            "type": "yesno",
            "id": "67fc546c18b1e36f2e000130",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39725663",
                "http://www.ncbi.nlm.nih.gov/pubmed/39708108",
                "http://www.ncbi.nlm.nih.gov/pubmed/39680210",
                "http://www.ncbi.nlm.nih.gov/pubmed/39674378",
                "http://www.ncbi.nlm.nih.gov/pubmed/39665989",
                "http://www.ncbi.nlm.nih.gov/pubmed/39647473",
                "http://www.ncbi.nlm.nih.gov/pubmed/39640943",
                "http://www.ncbi.nlm.nih.gov/pubmed/39632988"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725663",
                    "offsetInBeginSection": 634,
                    "offsetInEndSection": 743,
                    "text": "In vivo experiments were also carried out with a rat model for renal urolithiasis treated with linoleic acid.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39708108",
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 200,
                    "text": "patients with renal or ureteric stones.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39680210",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "Urolithiasis is a prevalent condition in urology, with extracorporeal shock wave lithotripsy (ESWL) serving as a common treatment for kidney stones under 2 cm.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39674378",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "text": "To assess urologists' perceptions and current practices of using suction-based techniques and technologies in percutaneous nephrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS) for kidney stones.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39674378",
                    "offsetInBeginSection": 844,
                    "offsetInEndSection": 981,
                    "text": "Around 55.69% believe that as evidence evolves, suction has the potential to be a game changer in endourology management of urolithiasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39665989",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "text": "Urolithiasis, a common and painful urological condition, is influenced by factors such as lifestyle, genetics, and medication. Differentiating between different types of kidney stones is crucial for personalized therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39647473",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "text": "Ureteral access sheaths (UASs) are widely used in the endoscopic treatment of urolithiasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39647473",
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 445,
                    "text": "This retrospective study included 1,026 patients who received ureterorenoscopic treatment for nephrolithiasis between 2016 and 2018 at a large academic center.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39640943",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Urolithiasis is a common urological problem that is associated with high morbidity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39632988",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "numerous epidemiological studies demonstrate the correlation between obesity and urolithiasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is urolithiasis the same thing as kidney stones?",
            "type": "yesno",
            "id": "67cde41a81b102733300001d",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39303995",
                "http://www.ncbi.nlm.nih.gov/pubmed/39290878",
                "http://www.ncbi.nlm.nih.gov/pubmed/36611268",
                "http://www.ncbi.nlm.nih.gov/pubmed/35237433",
                "http://www.ncbi.nlm.nih.gov/pubmed/37597788",
                "http://www.ncbi.nlm.nih.gov/pubmed/35736986",
                "http://www.ncbi.nlm.nih.gov/pubmed/32628928",
                "http://www.ncbi.nlm.nih.gov/pubmed/39009475",
                "http://www.ncbi.nlm.nih.gov/pubmed/32695146",
                "http://www.ncbi.nlm.nih.gov/pubmed/32805296"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39303995",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 379,
                    "text": "Crotalidae immune F(ab')2 (equine) (ANAVIP), given as treatment for Crotalidae envenomation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39290878",
                    "offsetInBeginSection": 650,
                    "offsetInEndSection": 786,
                    "text": "We produced this antivenom from the plasma of horses immunized with eight medically important venoms of viperid snake species from MENA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36611268",
                    "offsetInBeginSection": 900,
                    "offsetInEndSection": 1037,
                    "text": "LC-MS/MS further identified the proteins as equine immunoglobulins, representing the key therapeutic ingredient of this biologic product.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35237433",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 351,
                    "text": "The only available standard drug used for the treatment of SBE is antisnake venom (ASV) which consists of immunoglobulins that have been purified from the plasma of animals hyper-immunized against snake venoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37597788",
                    "offsetInBeginSection": 1380,
                    "offsetInEndSection": 1694,
                    "text": "Similarly, there are monovalent or polyvalent anti-serums used for the production of anti-venom depending on the snake species and the number of snakebites occurred in that area, e.g., Soro antibotropicocrotalico contains specific antibodies for Pit vipers and rattlesnakes, and Antielapidico targets coral snakes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35736986",
                    "offsetInBeginSection": 94,
                    "offsetInEndSection": 208,
                    "text": "Snake venom antiserum is the only approved and effective treatment available, but for selected snake species only.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32628928",
                    "offsetInBeginSection": 77,
                    "offsetInEndSection": 184,
                    "text": "The only mainstay treatment depends on the administration of animal derived immunoglobulin based antivenom.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39009475",
                    "offsetInBeginSection": 1348,
                    "offsetInEndSection": 1522,
                    "text": "In respect of antivenom therapy, administration of tiger snake antivenom is supported by the binding data, but due to the low cross reactivity multiple vials may be required.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37597788",
                    "offsetInBeginSection": 1179,
                    "offsetInEndSection": 1379,
                    "text": "anti-serums are available commercially to prevent the adverse effects of snakebite, which are species-specific, expensive, have inadequate pharmacology and impaired interaction with the immune system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32695146",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "The production of antivenom from immunized animals is an established treatment for snakebites;",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What do snake antivenoms contain?",
            "type": "summary",
            "id": "680f4aa6353a4a2e6b000008",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35511433",
                "http://www.ncbi.nlm.nih.gov/pubmed/35438172",
                "http://www.ncbi.nlm.nih.gov/pubmed/35065053",
                "http://www.ncbi.nlm.nih.gov/pubmed/32292406",
                "http://www.ncbi.nlm.nih.gov/pubmed/30833511",
                "http://www.ncbi.nlm.nih.gov/pubmed/30602457",
                "http://www.ncbi.nlm.nih.gov/pubmed/25998393",
                "http://www.ncbi.nlm.nih.gov/pubmed/25470051",
                "http://www.ncbi.nlm.nih.gov/pubmed/25132502"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35511433",
                    "offsetInBeginSection": 213,
                    "offsetInEndSection": 449,
                    "text": "Recent studies in mice indicate that microglia are derived exclusively from primitive yolk sac hematopoiesis and self-renew without contribution from ontogenically distinct monocytes/macrophages of definitive adult hematopoietic origin.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35511433",
                    "offsetInBeginSection": 665,
                    "offsetInEndSection": 918,
                    "text": "Moreover, peripheral monocytes contributed to a higher fraction of macrophages in the choroid plexus, meninges, and perivascular spaces of aged AD mice versus WT control mice, indicating enrichment at potential sites for entry into the brain parenchyma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35438172",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 838,
                    "text": "Single-cell RNA-sequencing revealed transcriptional similarities between placenta macrophages and erythro-myeloid progenitor-derived fetal liver macrophages and microglia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35438172",
                    "offsetInBeginSection": 839,
                    "offsetInEndSection": 1090,
                    "text": "As with other fetal tissue macrophages, HBCs were dependent on the transcription factor Pu.1, the loss-of-function of which in embryos disrupted fetoplacental labyrinth morphology, supporting a role for HBC in labyrinth angiogenesis and/or remodeling.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065053",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 438,
                    "text": "Primitive microglia arise from extraembryonic progenitors in the yolk sac (YS). The extraembryonic origins of primitive microglia are distinct from other tissue macrophages.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32292406",
                    "offsetInBeginSection": 255,
                    "offsetInEndSection": 464,
                    "text": "Microglia are similar, but not identical to other tissue macrophages, and in this review, we will first summarize the differences in the origin, lineage and population maintenance of microglia and macrophages.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30833511",
                    "offsetInBeginSection": 1285,
                    "offsetInEndSection": 1487,
                    "text": "Immunohistochemistry, flow cytometry, and genetic lineage tracing showed that infiltrating CCR2 cells include T cells, dendritic cells, and monocytes, the latter differentiating into tissue macrophages.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30602457",
                    "offsetInBeginSection": 366,
                    "offsetInEndSection": 634,
                    "text": "Resident microglia and invading macrophages have been shown to have distinct origin and function. Whereas yolk sac-derived microglia reside in the brain, blood-derived monocytes invade the central nervous system only under pathological conditions like tumor formation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25998393",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 265,
                    "text": "Recent studies suggest that microglia are a unique myeloid population distinct from peripheral macrophages in terms of origin and gene expression signature.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470051",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Most haematopoietic cells renew from adult haematopoietic stem cells (HSCs), however, macrophages in adult tissues can self-maintain independently of HSCs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are microglia derived from the same lineage as peripheral macrophages?",
            "type": "yesno",
            "id": "680a078618b1e36f2e000146",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39617422",
                "http://www.ncbi.nlm.nih.gov/pubmed/39378973",
                "http://www.ncbi.nlm.nih.gov/pubmed/38838150",
                "http://www.ncbi.nlm.nih.gov/pubmed/38481312",
                "http://www.ncbi.nlm.nih.gov/pubmed/38316202",
                "http://www.ncbi.nlm.nih.gov/pubmed/37810262",
                "http://www.ncbi.nlm.nih.gov/pubmed/36791892",
                "http://www.ncbi.nlm.nih.gov/pubmed/36729270",
                "http://www.ncbi.nlm.nih.gov/pubmed/36717725",
                "http://www.ncbi.nlm.nih.gov/pubmed/36606611"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39617422",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 213,
                    "text": "Among the intrathecal inflammatory niches where compartmentalized inflammation persists and plays a pivotal role in progressive multiple sclerosis (MS), choroid plexus (CP) has recently received renewed attention.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39617422",
                    "offsetInBeginSection": 671,
                    "offsetInEndSection": 754,
                    "text": "Significant inflammation was detected in the CP of 21 out of the 40 MS cases (52%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39378973",
                    "offsetInBeginSection": 252,
                    "offsetInEndSection": 423,
                    "text": "However, recent research has revealed the critical role of peripheral immune cells located in key brain regions like the meninges, choroid plexus, and perivascular spaces.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38838150",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 370,
                    "text": "Choroid plexus (ChP) plays critical roles in barrier function and immune response modulation and expresses the ACE2 receptor and the chromosome 21-encoded TMPRSS2 protease, suggesting its substantial role in establishing SARS-CoV-2 infection in the brain.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38481312",
                    "offsetInBeginSection": 420,
                    "offsetInEndSection": 609,
                    "text": "BAMs, mostly located in the choroid plexus, meningeal and perivascular spaces, are now gaining increased attention due to advancements in multi-omics technologies and genetic methodologies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38481312",
                    "offsetInBeginSection": 853,
                    "offsetInEndSection": 985,
                    "text": "BAMs are believed to regulate neuroimmune responses associated with brain barriers and contribute to immune-mediated neuropathology.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38316202",
                    "offsetInBeginSection": 434,
                    "offsetInEndSection": 623,
                    "text": "BAMs, mostly located in the choroid plexus, meningeal and perivascular spaces, are now gaining increased attention due to advancements in multi-omics technologies and genetic methodologies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38316202",
                    "offsetInBeginSection": 867,
                    "offsetInEndSection": 999,
                    "text": "BAMs are believed to regulate neuroimmune responses associated with brain barriers and contribute to immune-mediated neuropathology.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37810262",
                    "offsetInBeginSection": 1111,
                    "offsetInEndSection": 1236,
                    "text": "Neuroinflammatory responses in the choroid plexus of the third ventricle may contribute due to its proximity to the habenula.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36791892",
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 849,
                    "text": "aging induces an accumulation of T cells in the choroid plexus, that is partially blunted following microbiota depletion.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the role of the choroid plexus in immune surveillance?",
            "type": "summary",
            "id": "680a21ff18b1e36f2e000151",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36592609",
                "http://www.ncbi.nlm.nih.gov/pubmed/36194179",
                "http://www.ncbi.nlm.nih.gov/pubmed/35737727",
                "http://www.ncbi.nlm.nih.gov/pubmed/35599392",
                "http://www.ncbi.nlm.nih.gov/pubmed/34584813",
                "http://www.ncbi.nlm.nih.gov/pubmed/34425917",
                "http://www.ncbi.nlm.nih.gov/pubmed/33967679",
                "http://www.ncbi.nlm.nih.gov/pubmed/33018515",
                "http://www.ncbi.nlm.nih.gov/pubmed/31372495",
                "http://www.ncbi.nlm.nih.gov/pubmed/29895614"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36592609",
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 218,
                    "text": "The interstitial cells of Cajal (ICC), specialised pacemaker cells, initiate and propagate these slow waves.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36592609",
                    "offsetInBeginSection": 732,
                    "offsetInEndSection": 1065,
                    "text": "To reduce computational costs, an adaptive multi-scale discretisation strategy for the temporal resolution of the electric field is used. The model incorporates a biophysically based model of gastric ICC pacemaker activity that aims to simulate stable entrainment and physiological conduction velocities of the electrical slow waves.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36592609",
                    "offsetInBeginSection": 1448,
                    "offsetInEndSection": 1734,
                    "text": "The results show that the ectopic event is accompanied by smooth muscle contraction and, although it disrupts the normal propagation pattern of gastric slow electrical waves, it can also catalyse the process of handling indigestible materials that might otherwise injure the gastric SW.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36194179",
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 314,
                    "text": "Pacing primarily regulates gut motility by modulating rhythmic bio-electrical events called slow waves.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35737727",
                    "offsetInBeginSection": 1219,
                    "offsetInEndSection": 1453,
                    "text": "There is a significant disruption in specialized interstitial cells of Cajal in the gastric antrum following sleeve gastrectomy. This is associated with a loss of gastric pacemaker activity and post-junctional neuroeffector responses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35737727",
                    "offsetInBeginSection": 1454,
                    "offsetInEndSection": 1593,
                    "text": "Over a 4-month recovery period there was a gradual return in interstitial cells of Cajal networks, pacemaker activity and neural responses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35599392",
                    "offsetInBeginSection": 1518,
                    "offsetInEndSection": 1707,
                    "text": "The composite mechanism includes the retention of gastric electrical pacemaker in greater curvature of the middle part of gastric body to increase the emptying capacity of residual stomach,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34584813",
                    "offsetInBeginSection": 808,
                    "offsetInEndSection": 927,
                    "text": "One such intervention is gastric electrical stimulation or gastric pacemaker, which aids in improving gastric motility.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34425917",
                    "offsetInBeginSection": 320,
                    "offsetInEndSection": 549,
                    "text": "A leadless inductively-powered pacemaker was implanted on the gastric serosa in an anesthetized pig. Wireless pacing was performed at transmitter-to-receiver distances up to 20 mm, frequency of 0.05 Hz, and pulse width of 400 ms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34425917",
                    "offsetInBeginSection": 550,
                    "offsetInEndSection": 729,
                    "text": "Electrogastrogram (EGG) recordings using cutaneous and serosal electrode arrays were analyzed to compute spectral and spatial statistical parameters associated with the slow wave.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "How does a gastric pacemaker work?",
            "type": "summary",
            "id": "67e098cb18b1e36f2e00006d",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39622251",
                "http://www.ncbi.nlm.nih.gov/pubmed/39617117",
                "http://www.ncbi.nlm.nih.gov/pubmed/39569720",
                "http://www.ncbi.nlm.nih.gov/pubmed/39472112",
                "http://www.ncbi.nlm.nih.gov/pubmed/39337513",
                "http://www.ncbi.nlm.nih.gov/pubmed/39207647",
                "http://www.ncbi.nlm.nih.gov/pubmed/39687987",
                "http://www.ncbi.nlm.nih.gov/pubmed/39647568",
                "http://www.ncbi.nlm.nih.gov/pubmed/39613397",
                "http://www.ncbi.nlm.nih.gov/pubmed/39603447"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39622251",
                    "offsetInBeginSection": 751,
                    "offsetInEndSection": 843,
                    "text": "The mean age at presentation of those with NVG was 30 months (median 25, range 0-120 months)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39617117",
                    "offsetInBeginSection": 785,
                    "offsetInEndSection": 863,
                    "text": "Based on billing codes, 208 eyes (4.1%) had primary congenital glaucoma (PCG),",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39569720",
                    "offsetInBeginSection": 811,
                    "offsetInEndSection": 981,
                    "text": "Ocular anomalies included nystagmus, epicanthus, lagophthalmos, entropion, megalocornea, corneal clouding, infantile glaucoma, high myopia, and retinal hyperpigmentation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39472112",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "To report the occurrence of unilateral, neonatal-onset congenital glaucoma in a child with Rubinstein-Taybi Syndrome (RTS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39337513",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Primary congenital glaucoma (PCG) occurs in children due to developmental abnormalities in the trabecular meshwork and anterior chamber angle.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39207647",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 440,
                    "text": "The patients were categorized into three groups: primary congenital glaucoma (PCG), secondary childhood glaucoma, and glaucoma following cataract surgery (GFCS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can newborns have glaucoma?",
            "type": "yesno",
            "id": "67d6be8a18b1e36f2e000022",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39542468",
                "http://www.ncbi.nlm.nih.gov/pubmed/39398592",
                "http://www.ncbi.nlm.nih.gov/pubmed/38952405",
                "http://www.ncbi.nlm.nih.gov/pubmed/38829438",
                "http://www.ncbi.nlm.nih.gov/pubmed/38700037",
                "http://www.ncbi.nlm.nih.gov/pubmed/38695330",
                "http://www.ncbi.nlm.nih.gov/pubmed/39115473",
                "http://www.ncbi.nlm.nih.gov/pubmed/39484132",
                "http://www.ncbi.nlm.nih.gov/pubmed/38424490",
                "http://www.ncbi.nlm.nih.gov/pubmed/38155547"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39542468",
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 464,
                    "text": "POD has a significant impact on the prognosis of older patients undergoing major cardiovascular surgery, including increased length of hospital stay, hospital costs and readmission rates, with an incidence rate as high as 26%-52%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39398592",
                    "offsetInBeginSection": 1064,
                    "offsetInEndSection": 1164,
                    "text": "Of the included 214 patients, 49 patients experienced delirium, resulting in an incidence of 22.90%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38952405",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 213,
                    "text": "Postoperative delirium (POD) is a common postoperative complication, especially in patients over 60 years, with an incidence ranging from 15% to 50%. In most cases, POD manifests in the first 5 days after surgery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38829438",
                    "offsetInBeginSection": 582,
                    "offsetInEndSection": 644,
                    "text": "A total of 134 (12.97%) patients were diagnosed with delirium.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38700037",
                    "offsetInBeginSection": 663,
                    "offsetInEndSection": 766,
                    "text": "A total of 212 patients were enrolled, with 25.0% of patients developing POD and 32.5% developing POCD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38695330",
                    "offsetInBeginSection": 680,
                    "offsetInEndSection": 929,
                    "text": "The weighted pooled incidence of delirium following open cardiac surgery across all studies was 23% (95% CI 20-26%), however we found a considerable heterogeneity (I2 = 99%), which could not be explained by subgroups or further sensitivity analyses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39115473",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "text": "Postoperative delirium (POD) is one of the most frequent complications after surgery which is closely associated with many adverse outcomes, including high mortality and low quality of life.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39484132",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Delirium is a frequent and serious complication of cardiac procedures that can lead to serious long-term health restrictions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38424490",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Postoperative delirium is a frequent and severe complication after cardiac surgery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38155547",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Delirium is the most common neurological complication after cardiac surgery with adverse impacts on surgical outcomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is delirium a frequent complication after cardiac surgery?",
            "type": "yesno",
            "id": "67f857eb18b1e36f2e000105",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39701285",
                "http://www.ncbi.nlm.nih.gov/pubmed/39281039",
                "http://www.ncbi.nlm.nih.gov/pubmed/39728613",
                "http://www.ncbi.nlm.nih.gov/pubmed/39578269",
                "http://www.ncbi.nlm.nih.gov/pubmed/39731246",
                "http://www.ncbi.nlm.nih.gov/pubmed/39653332",
                "http://www.ncbi.nlm.nih.gov/pubmed/39407446",
                "http://www.ncbi.nlm.nih.gov/pubmed/39726471",
                "http://www.ncbi.nlm.nih.gov/pubmed/39678427",
                "http://www.ncbi.nlm.nih.gov/pubmed/39667368"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39701285",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "Graves disease (GD) is the most common cause of hyperthyroidism.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39281039",
                    "offsetInBeginSection": 76,
                    "offsetInEndSection": 287,
                    "text": "Graves' disease (GD), as an autoimmune thyroid disease (AITD), is attributed to the production of thyroid-stimulating hormone receptor (TSHR) autoantibodies that bind to the thyroid follicular endothelial cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728613",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Graves' disease, a common autoimmune disorder, characteristically presents with upper eyelid retraction, causing significant functional and cosmetic concerns for affected individuals.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39578269",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Graves' ophthalmopathy is the most common extra-thyroidal organ manifestation of Graves' disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39731246",
                    "offsetInBeginSection": 353,
                    "offsetInEndSection": 484,
                    "text": "The pathogenesis of EO is primarily attributed to cross-reactive immune activity between thyroid antigens and orbital soft tissues.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39653332",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Thyrotropin receptor antibodies (TRAb) are specific for Graves' disease (GD) and play a crucial role in the pathogenesis of GD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39701285",
                    "offsetInBeginSection": 65,
                    "offsetInEndSection": 149,
                    "text": "Treatment options include antithyroid drugs (ATDs), radioactive iodine, and surgery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39701285",
                    "offsetInBeginSection": 600,
                    "offsetInEndSection": 755,
                    "text": "ATDs are currently the preferred option for initial management of GD, reflecting a shift in practice observed in the United States over the past 2 decades.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39701285",
                    "offsetInBeginSection": 1106,
                    "offsetInEndSection": 1365,
                    "text": "Medical management of GD with antithyroid drug is safe and effective. Long-term use beyond 24 months in patients with elevated thyrotropin receptor antibody is a reasonable alternative option to surgery and radioactive iodine due to higher rates of remission.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39407446",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Graves' hyperthyroidism is characterized by stimulation of the thyroid gland by thyroid-stimulating hormone receptor antibodies (TRAbs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please summarize Graves disease",
            "type": "summary",
            "id": "67cde43c81b102733300001e",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39726592",
                "http://www.ncbi.nlm.nih.gov/pubmed/39723764",
                "http://www.ncbi.nlm.nih.gov/pubmed/39719214",
                "http://www.ncbi.nlm.nih.gov/pubmed/39696625",
                "http://www.ncbi.nlm.nih.gov/pubmed/39691280",
                "http://www.ncbi.nlm.nih.gov/pubmed/39672171",
                "http://www.ncbi.nlm.nih.gov/pubmed/39667569",
                "http://www.ncbi.nlm.nih.gov/pubmed/39653621",
                "http://www.ncbi.nlm.nih.gov/pubmed/39640775",
                "http://www.ncbi.nlm.nih.gov/pubmed/39620588"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726592",
                    "offsetInBeginSection": 83,
                    "offsetInEndSection": 184,
                    "text": "Recent advances in immunotherapy have introduced promising treatments targeting T cell functionality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726592",
                    "offsetInBeginSection": 407,
                    "offsetInEndSection": 621,
                    "text": "This review addresses the critical challenge of T cell exhaustion in non-small cell lung cancer (NSCLC), offering a detailed examination of its molecular underpinnings and the resultant therapeutic ineffectiveness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726592",
                    "offsetInBeginSection": 622,
                    "offsetInEndSection": 844,
                    "text": "We synthesize current knowledge on the drivers of T cell exhaustion, evaluate emerging strategies for its reversal, and explore the potential impact of these insights for enhancing the clinical efficacy of immunotherapies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39723764",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 231,
                    "text": "Despite recent advances in immunotherapy against B cell malignancies such as BCMA (B cell maturation antigen) and CD19-targeted treatments using soluble T cell-engaging (TCE) antibodies or chimeric antigen receptor T cells (CAR-T),",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39723764",
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 628,
                    "text": "Approaches to avoid tumor-intrinsic mechanisms of resistance such as immune pressure-mediated antigen downmodulation, are being broadly investigated. These strategies include BCMA/CD19 dual-targeting therapies, which may be of particular interest to patients with B cell lymphoma and multiple myeloma,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39719214",
                    "offsetInBeginSection": 376,
                    "offsetInEndSection": 538,
                    "text": "In this review, we discuss how physical characteristics influence effector functions and innate immune signaling pathways in distinct innate immune cell subtypes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39696625",
                    "offsetInBeginSection": 125,
                    "offsetInEndSection": 296,
                    "text": "Among these immunotherapies, messenger ribonucleic acid (mRNA) cancer vaccines are worthy of consideration, as they have demonstrated promising results in clinical trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39696625",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 509,
                    "text": "They can be easily mass-produced in a relatively short time and induce a systemic immune response effective against both the primary tumor and metastases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39696625",
                    "offsetInBeginSection": 510,
                    "offsetInEndSection": 621,
                    "text": "Transcripts encoding immunomodulatory molecules can also be incorporated into the mRNA, enhancing its efficacy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39696625",
                    "offsetInBeginSection": 831,
                    "offsetInEndSection": 1134,
                    "text": "Many innovations have been suggested to overcome these obstacles, including structural modification (such as 5' cap modification), optimizing delivery vehicles (especially dendritic cells (DCs) and nanoparticles), and using antigens that can enhance immunogenicity by circumventing tolerance mechanisms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are some recent advances in cancer immunotherapy?",
            "type": "list",
            "id": "680bc74618b1e36f2e000155",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39645539",
                "http://www.ncbi.nlm.nih.gov/pubmed/39527116",
                "http://www.ncbi.nlm.nih.gov/pubmed/39723733",
                "http://www.ncbi.nlm.nih.gov/pubmed/39604371",
                "http://www.ncbi.nlm.nih.gov/pubmed/39718074",
                "http://www.ncbi.nlm.nih.gov/pubmed/39545512",
                "http://www.ncbi.nlm.nih.gov/pubmed/39542111"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39645539",
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 693,
                    "text": "Genome-wide DNA methylation was examined in the dorsolateral prefrontal cortex of depressed suicide (MDD+S; n = 15), depressed non-suicide (MDD-S; n = 17), and nonpsychiatric control (C; n = 16) subjects using 850 K Infinium Methylation EPIC BeadChip.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39645539",
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 441,
                    "text": "The present study examined if DNA methylation changes can distinguish suicidal behavior among depressed subjects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39645539",
                    "offsetInBeginSection": 1499,
                    "offsetInEndSection": 1707,
                    "text": "Altogether, our data show a distinct pattern of DNA methylation, the genomic distribution of differentially methylated sites, gene enrichment, and pathways in MDD suicide compared to non-suicide MDD subjects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39527116",
                    "offsetInBeginSection": 947,
                    "offsetInEndSection": 1261,
                    "text": "Following our literature search and meta-analyses on 20 NTRK2 SNPs across up to 8467 samples, we found three SNPs, rs10868235 [N = 5,318, odds ratio (OR) = 1.34, P = 0.02], rs1867283 (N = 5,134, OR = 0.73, P = 0.04), and rs1147198 (N = 5,132, OR = 1.36, P = 0.03) to be nominally associated with suicidal attempts.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39527116",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 493,
                    "text": "In the current study, we aim to examine the potential association between NTRK2 single nucleotide polymorphism (SNPs) and suicidal ideation/behaviors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39527116",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 238,
                    "text": "Previous studies have shown that genes in brain development pathways may have important roles in affecting risk of suicidal behaviors, with our previous meta-analysis supporting a role of the brain-derived neurotrophic factor (BDNF) gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39527116",
                    "offsetInBeginSection": 1421,
                    "offsetInEndSection": 1502,
                    "text": "Our results suggest that the NTRK2 gene may not have a major role in suicidality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39645539",
                    "offsetInBeginSection": 1381,
                    "offsetInEndSection": 1498,
                    "text": "Functional analysis suggested oxytocin, GABA, VGFA, TNFA, and mTOR pathways associated with suicide in the MDD group.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39723733",
                    "offsetInBeginSection": 1347,
                    "offsetInEndSection": 1481,
                    "text": "For instance, suicidality in BD has physiological causal factors, e.g., genetic predisposition and aggravation by symptomatic periods.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39604371",
                    "offsetInBeginSection": 506,
                    "offsetInEndSection": 763,
                    "text": "In this study, we compared the protein expression levels of genes encoding tricarboxylic acid (TCA) cycle enzymes in the PHC of adult individuals who died by suicide by reverse phase protein array (RPPA), which was corroborated by qRT-PCR at the mRNA level.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are there any studies on the genetics of suicide?",
            "type": "yesno",
            "id": "67e2958018b1e36f2e000084",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39732660",
                "http://www.ncbi.nlm.nih.gov/pubmed/39728994",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739642",
                "http://www.ncbi.nlm.nih.gov/pubmed/39728102",
                "http://www.ncbi.nlm.nih.gov/pubmed/39716009",
                "http://www.ncbi.nlm.nih.gov/pubmed/39716962",
                "http://www.ncbi.nlm.nih.gov/pubmed/39732335",
                "http://www.ncbi.nlm.nih.gov/pubmed/39728482",
                "http://www.ncbi.nlm.nih.gov/pubmed/39710032",
                "http://www.ncbi.nlm.nih.gov/pubmed/39742284"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39732660",
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 605,
                    "text": "Total proteome and nine PTMs (phosphorylation, acetylation, crotonylation, ubiquitination, lactylation, N-glycosylation, succinylation, malonylation, and -hydroxybutyrylation) in tumor sections and paired normal adjacent tissues derived from 18 HCC patients were systematically profiled by 4D-Label free proteomics analysis combined with PTM-based peptide enrichment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728994",
                    "offsetInBeginSection": 289,
                    "offsetInEndSection": 478,
                    "text": "We discuss the various types of PTMs, including phosphorylation, ubiquitination, SUMoylation, acetylation, glycosylation, palmitoylation, and lactylation, that occur during PRRSV infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739642",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Protein glycosylation, a vital post-translational modification, is pivotal in various biological processes and disease pathogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728102",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Glycosylation is a ubiquitous and the most structurally diverse post-translational modification of proteins.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39716009",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 213,
                    "text": "Protein phosphorylation is an important post-translational modification that regulates almost all cellular processes, such as cellular metabolism, growth, differentiation, signal transduction, and gene regulation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39716962",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Ubiquitination is a dynamic post-translational modification governing protein abundance, function, and localization in eukaryotes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39732335",
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 585,
                    "text": "S-palmitoylation (commonly referred to as palmitoylation), a post-translational modification (PTM) characterized by the covalent linkage of a 16-carbon palmitic acid (PA) chain to specific cysteine residues on target proteins, plays a pivotal role in diverse cellular functions and is intimately associated with the liver's physiological and pathological states.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728482",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "text": "Acetylation-Mediated Post-Translational Modification of Pyruvate Dehydrogenase Plays a Critical Role in the Regulation of the Cellular Acetylome During Metabolic Stress.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39710032",
                    "offsetInBeginSection": 601,
                    "offsetInEndSection": 742,
                    "text": "Methylation modifications on non-histone lysine and arginine residues have been identified as common PTMs critical to various life processes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39742284",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine to serine and threonine residues.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are some common post-translational modifications of proteins?",
            "type": "list",
            "id": "680c174d353a4a2e6b000001",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39740961",
                "http://www.ncbi.nlm.nih.gov/pubmed/39740618",
                "http://www.ncbi.nlm.nih.gov/pubmed/39729591",
                "http://www.ncbi.nlm.nih.gov/pubmed/39694862",
                "http://www.ncbi.nlm.nih.gov/pubmed/39693869",
                "http://www.ncbi.nlm.nih.gov/pubmed/39681252",
                "http://www.ncbi.nlm.nih.gov/pubmed/39656569",
                "http://www.ncbi.nlm.nih.gov/pubmed/39652667",
                "http://www.ncbi.nlm.nih.gov/pubmed/39639581",
                "http://www.ncbi.nlm.nih.gov/pubmed/39636869"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740961",
                    "offsetInBeginSection": 1243,
                    "offsetInEndSection": 1332,
                    "text": "Kinesiophobia negatively affects patients' functional status and overall quality of life.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740618",
                    "offsetInBeginSection": 976,
                    "offsetInEndSection": 1131,
                    "text": "The children and adolescents with ADHD had an increased risk of specific phobia versus those without ADHD (pooled RR = 1.68, 95%CI = 1.16-2.44, P = 0.006).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740618",
                    "offsetInBeginSection": 1132,
                    "offsetInEndSection": 1268,
                    "text": "The risk of social phobia in the ADHD group was higher than that in the non-ADHD group (pooled RR = 1.71, 95%CI = 1.13-2.61, P = 0.012).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740618",
                    "offsetInBeginSection": 1269,
                    "offsetInEndSection": 1431,
                    "text": "The children and adolescents with ADHD were at an elevated risk of agoraphobia compared with those without ADHD (pooled RR = 4.99, 95%CI = 1.51-16.56, P = 0.009).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39729591",
                    "offsetInBeginSection": 905,
                    "offsetInEndSection": 1021,
                    "text": "Primary appraisal factors, such as fear of reinjury, kinesiophobia, and anxiety, emerged as significant influencers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39694862",
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 385,
                    "text": "Fear of cancer recurrence (FCR) is well-documented in cancer survivors, however AYA survivors of breast and gynaecological cancers are less well-studied. Moreover, little is known about scan-related fears and anxiety ('scanxiety') in survivors of any age group.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39694862",
                    "offsetInBeginSection": 1013,
                    "offsetInEndSection": 1126,
                    "text": "Both FCR and scanxiety were prevalent, with 84% reporting clinically meaningful FCR and 38% reporting severe FCR.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39693869",
                    "offsetInBeginSection": 551,
                    "offsetInEndSection": 829,
                    "text": "Forty-seven spider-fearful individuals were randomly assigned to receive either a one-session in-vivo standard exposure treatment (Exp-Only) or an one-session in-vivo exposure treatment supplemented with occasional mental imagery of their worst-case spider scenario (Exp + ORE).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39693869",
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1184,
                    "text": "Both groups showed improvement from baseline to post-assessment, but the Exp + ORE group demonstrated significantly greater reductions in self-reported fear and avoidance of spiders compared to standard exposure training.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39693869",
                    "offsetInBeginSection": 1413,
                    "offsetInEndSection": 1624,
                    "text": "Findings moreover indicate that occasional imagery during exposure lead to greater expectancy violation compared to standard exposure, providing insights into potential underlying mechanisms of the ORE approach.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Phobias affecting humans.",
            "type": "list",
            "id": "67e291a718b1e36f2e000081",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39741501",
                "http://www.ncbi.nlm.nih.gov/pubmed/39740533",
                "http://www.ncbi.nlm.nih.gov/pubmed/39740472",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739290",
                "http://www.ncbi.nlm.nih.gov/pubmed/39738216",
                "http://www.ncbi.nlm.nih.gov/pubmed/39736796",
                "http://www.ncbi.nlm.nih.gov/pubmed/39735601",
                "http://www.ncbi.nlm.nih.gov/pubmed/39735600",
                "http://www.ncbi.nlm.nih.gov/pubmed/39735531",
                "http://www.ncbi.nlm.nih.gov/pubmed/39735191"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39741501",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Deep learning-based radiomics techniques have the potential to aid specialists and physicians in performing decision-making in COVID-19 scenarios.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39741501",
                    "offsetInBeginSection": 523,
                    "offsetInEndSection": 648,
                    "text": "We use deep learning models to extract deep radiomics features and evaluate its performance regarding end-to-end classifiers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740533",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 630,
                    "text": "We used a nnU-Net model, a state-of-the-art deep learning-based segmentation algorithm that automatically configures image preprocessing, network architecture, training, and post-processing to identify the IP attachment site.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740472",
                    "offsetInBeginSection": 685,
                    "offsetInEndSection": 1077,
                    "text": "To harness the potential benefits of exploiting correlations among signals in adjacent voxels, this study introduces a novel approach to deep learning parameter estimation that effectively incorporates relevant spatial information. This is achieved by training neural networks on patches of synthetic data encompassing plausible combinations of direct correlations between neighboring voxels.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740472",
                    "offsetInBeginSection": 1161,
                    "offsetInEndSection": 1307,
                    "text": "We explored the potential of several deep learning architectures to incorporate spatial information using self-supervised and supervised learning.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740472",
                    "offsetInBeginSection": 1456,
                    "offsetInEndSection": 1803,
                    "text": "Additionally, we present results of the approach applied to in vivo DWI data consisting of twelve repetitions from a healthy volunteer. We demonstrate that supervised training on larger patch sizes using attention models leads to substantial performance improvements over both conventional voxelwise model fitting and convolution-based approaches.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739290",
                    "offsetInBeginSection": 1231,
                    "offsetInEndSection": 1401,
                    "text": "Additionally, the use of synthetic data in training convolutional neural networks demonstrated robustness in detecting hemarthrosis, especially with limited sample sizes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39738216",
                    "offsetInBeginSection": 498,
                    "offsetInEndSection": 603,
                    "text": "A deep learning model (DLM) was trained on volumes of lesions on baseline CT to predict clinical benefit.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39736796",
                    "offsetInBeginSection": 874,
                    "offsetInEndSection": 924,
                    "text": "DL features were obtained using a 3D ResNet model.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39735601",
                    "offsetInBeginSection": 160,
                    "offsetInEndSection": 293,
                    "text": "The advanced Inception V3 model to predict EGFR mutations based on PET/CT images and developed CT, PET, and PET + CT models was used.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "How can convolutional neural networks (CNNs) be utilized in radiomics?",
            "type": "summary",
            "id": "680b7f4818b1e36f2e000154",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38018344",
                "http://www.ncbi.nlm.nih.gov/pubmed/33660452",
                "http://www.ncbi.nlm.nih.gov/pubmed/36726595",
                "http://www.ncbi.nlm.nih.gov/pubmed/35514536",
                "http://www.ncbi.nlm.nih.gov/pubmed/35461918",
                "http://www.ncbi.nlm.nih.gov/pubmed/33377541",
                "http://www.ncbi.nlm.nih.gov/pubmed/31828966",
                "http://www.ncbi.nlm.nih.gov/pubmed/36455546",
                "http://www.ncbi.nlm.nih.gov/pubmed/31749341"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38018344",
                    "offsetInBeginSection": 994,
                    "offsetInEndSection": 1061,
                    "text": "static(s) ORP in semen was measured by means of a MiOXSYS analyser.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33660452",
                    "offsetInBeginSection": 781,
                    "offsetInEndSection": 833,
                    "text": "The sORP was measured by using the MiOXSYSTM system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36726595",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "The MiOXSYS system is a new technique to analyze the semen oxidative reduction potential (ORP) that may use to classify the level of sperm DNA integrity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35514536",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "Male Infertility Oxidative System (MiOXSYS) has been proposed as a rapid and promising technology for the evaluation of sperm oxidative stress.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35461918",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "To assess whether varicocele repair improves oxidative stress (OS) measured by the MiOXSYS system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33377541",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 364,
                    "text": "Measurement of redox potential provides a more comprehensive assessment of OS, although the test has yet to be fully validated. This study aimed to validate the MiOX",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31828966",
                    "offsetInBeginSection": 577,
                    "offsetInEndSection": 694,
                    "text": "ORP was evaluated in 3968 patients using the MiOXSYS system and SDF in 1147 patients using the Halosperm G2 test kit.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36455546",
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 579,
                    "text": "To determine the natural fluctuations in semen redox indicators (MiOXSYS Total, 118 repeat semen samples from 31 generally healthy men aged 18-45 years, over 6 months. Standard semen analysis as per 5th WHO manual. Semen redox levels measured via MiOXSYS",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36455546",
                    "offsetInBeginSection": 580,
                    "offsetInEndSection": 638,
                    "text": "Samples with high redox-potential (MiOXSYS Neither MiOXSYS",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do MiOXSYS and OxiSperm measure ROS(Reactive Oxygen Species) in sperm?",
            "type": "yesno",
            "id": "67e0053118b1e36f2e000067",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39057949",
                "http://www.ncbi.nlm.nih.gov/pubmed/38203326",
                "http://www.ncbi.nlm.nih.gov/pubmed/37913983",
                "http://www.ncbi.nlm.nih.gov/pubmed/36869288",
                "http://www.ncbi.nlm.nih.gov/pubmed/36835612",
                "http://www.ncbi.nlm.nih.gov/pubmed/39642134",
                "http://www.ncbi.nlm.nih.gov/pubmed/39075923",
                "http://www.ncbi.nlm.nih.gov/pubmed/39061373",
                "http://www.ncbi.nlm.nih.gov/pubmed/38537648",
                "http://www.ncbi.nlm.nih.gov/pubmed/36945969"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39057949",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 320,
                    "text": "OnabotulinumtoxinA (BT-A) is used in different medical fields for its beneficial effects. BT-A, a toxin originally produced by the bacterium Clostridium botulinum, is widely known for its ability to temporarily paralyze muscles by blocking the release of acetylcholine, a neurotransmitter involved in muscle contraction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38203326",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "The cholinergic system, relying on the neurotransmitter acetylcholine (ACh), plays a significant role in muscle contraction, cognition, and autonomic nervous system regulation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37913983",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Acetylcholine is the primary excitatory neurotransmitter in visceral smooth muscles, wherein it binds to and activates two muscarinic receptors subtypes, M",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36869288",
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 348,
                    "text": "the arrival of the nerve impulse at the presynaptic terminal triggers the molecular mechanisms associated with ACh release, which can be retrogradely regulated by the resulting muscle contraction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36835612",
                    "offsetInBeginSection": 1189,
                    "offsetInEndSection": 1327,
                    "text": "In PD mice, nicotine increased Nurr1 expression, reduced the number of -syn-expressing neurons, and simultaneously rescued motor deficits.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What neurotransmitter is most associated with muscle activation?",
            "type": "factoid",
            "id": "680a07ed18b1e36f2e000149",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39725885",
                "http://www.ncbi.nlm.nih.gov/pubmed/39649586",
                "http://www.ncbi.nlm.nih.gov/pubmed/39633351",
                "http://www.ncbi.nlm.nih.gov/pubmed/39609754",
                "http://www.ncbi.nlm.nih.gov/pubmed/39596568",
                "http://www.ncbi.nlm.nih.gov/pubmed/39568431",
                "http://www.ncbi.nlm.nih.gov/pubmed/39522014",
                "http://www.ncbi.nlm.nih.gov/pubmed/39452740",
                "http://www.ncbi.nlm.nih.gov/pubmed/39449682",
                "http://www.ncbi.nlm.nih.gov/pubmed/39352168"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725885",
                    "offsetInBeginSection": 1801,
                    "offsetInEndSection": 1892,
                    "text": "All the cohort of women with schistosomiasis were anaemic (281.9 vs. 30 2.1, P = < 0.0001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725885",
                    "offsetInBeginSection": 2049,
                    "offsetInEndSection": 2222,
                    "text": "Schistosoama haematobium infection was more likely to cause lower maternal haematocrit levels than Schistosoama mansoni infection was (OR 4.72 95% CI 1.87-11.95, P < 0.001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39649586",
                    "offsetInBeginSection": 1166,
                    "offsetInEndSection": 1465,
                    "text": "Compared to sulfadoxine-pyrimethamine, dihydroarteminsinin-piperaquine was associated with a 69% [95% CI: 45%-82%] lower incidence of clinical malaria during pregnancy, a 62% [37%-77%] lower risk of placental parasitaemia, and a 17% [0%-31%] lower incidence of moderate maternal anaemia (Hb<9 g/dL).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39633351",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 670,
                    "text": "Children 6 months to 4 years of age admitted at Jinja and Mulago hospitals in Uganda, with one or more of the five most common forms of SM, cerebral malaria (n = 53), respiratory distress syndrome (n = 108), malaria with complicated seizures (n = 160), severe malarial anaemia (n = 155) or prostration (n = 75), were followed for 12 months after discharge, alongside asymptomatic community children (CC) (n = 120) of similar ages recruited from the households or neighbourhoods of the children with SM.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39609754",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "Toxoplasmosis, a parasitic disease, can cause fatal multi-organ failure in immunocompromised patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39596568",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "Trypanosomiasis and bovine babesiosis correspond to important diseases that cause great economic losses, but there are still no studies evaluating their occurrence in herds of dairy cattle in Ceara.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39568431",
                    "offsetInBeginSection": 1271,
                    "offsetInEndSection": 1539,
                    "text": "The relationship between malaria and SCD is complicated and discussed in this review. Unlike many of the genetic risk factors for poor outcomes in SCD, it is theoretically possible to modify the risks associated with infections with established public health measures.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39522014",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "Malaria is a major cause of ill health and death in children in Africa.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39452740",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "Severe malarial anemia (SMA, Hb < 6.0 g/dL) is a leading cause of childhood morbidity and mortality in holoendemic",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39449682",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Children with severe malarial anemia (SMA) typically have low in-hospital mortality but have a high risk of post-discharge readmission or death.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which parasitic infections can cause anemia?",
            "type": "list",
            "id": "67e2a8d618b1e36f2e000088",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32233999",
                "http://www.ncbi.nlm.nih.gov/pubmed/33407587"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32233999",
                    "offsetInBeginSection": 1271,
                    "offsetInEndSection": 1535,
                    "text": "In this network, HCP5, LINC00638, XIST and TP53TG1 were hub nodes. Functional analysis of this network identified some essential immune functions, hematopoietic functions, osteoclast differentiation, and primary immunodeficiency as associated with neonatal sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "XIST proteins mediate what cellular process?",
            "type": "factoid",
            "id": "67ca061181b102733300000a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39687652",
                "http://www.ncbi.nlm.nih.gov/pubmed/39583933",
                "http://www.ncbi.nlm.nih.gov/pubmed/39672284",
                "http://www.ncbi.nlm.nih.gov/pubmed/39626095",
                "http://www.ncbi.nlm.nih.gov/pubmed/39585008",
                "http://www.ncbi.nlm.nih.gov/pubmed/39609575",
                "http://www.ncbi.nlm.nih.gov/pubmed/39690003",
                "http://www.ncbi.nlm.nih.gov/pubmed/39621418",
                "http://www.ncbi.nlm.nih.gov/pubmed/39584369",
                "http://www.ncbi.nlm.nih.gov/pubmed/39734091"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39687652",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Obstructive sleep apnea (OSA) is often a lifestyle disease associated with obesity,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39583933",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "Obesity is a significant risk factor for obstructive sleep apnea (OSA).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39672284",
                    "offsetInBeginSection": 1601,
                    "offsetInEndSection": 1781,
                    "text": "These findings underscore obesity as the primary shared risk factor, highlighting the importance of weight management as a key strategy for mitigating the risks of both conditions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39626095",
                    "offsetInBeginSection": 1224,
                    "offsetInEndSection": 1379,
                    "text": "Obese individuals experienced a more significant decrease in AHI with an estimated treatment difference of -12.93 events per hour vs -4.31 events per hour.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39585008",
                    "offsetInBeginSection": 745,
                    "offsetInEndSection": 852,
                    "text": "Types of OSA included obstructive (97.05%), central (2.5%), and associated obesity-hypoventilation (39.7%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39609575",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "The occurrence of obstructive sleep apnea (OSA) syndrome is related to not only the overall obesity, but also the local distribution of fat.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39609575",
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1106,
                    "text": "WC and BMI emerged as the strongest diagnostic indicators of OSA risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39690003",
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 1106,
                    "text": "Clustering analysis identified three distinct phenotypes: Cluster 1 (middle-aged, severely obese, very severe OSA with nocturnal hypoxemia), Cluster 2 (young, overweight, moderate OSA with limited nocturnal hypoxemia), and Cluster 3 (elderly, obese, multimorbid, severe OSA with nocturnal hypoxemia).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39621418",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 579,
                    "text": "This review aims to summarize the potential impact of liraglutide, semaglutide, and tirzepatide in managing obese patients with OSA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39584369",
                    "offsetInBeginSection": 332,
                    "offsetInEndSection": 531,
                    "text": "Pregnant women with overweight/obesity and snoring were recruited at <13 weeks gestation and underwent level III home sleep apnea testing and 24-hour ABPM at enrollment and at 31-34 weeks' gestation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is obesity a risk factor for sleep apnea?",
            "type": "yesno",
            "id": "67e2bde318b1e36f2e000093",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36211205",
                "http://www.ncbi.nlm.nih.gov/pubmed/36075185",
                "http://www.ncbi.nlm.nih.gov/pubmed/35532771",
                "http://www.ncbi.nlm.nih.gov/pubmed/35167789",
                "http://www.ncbi.nlm.nih.gov/pubmed/34997298",
                "http://www.ncbi.nlm.nih.gov/pubmed/34848324",
                "http://www.ncbi.nlm.nih.gov/pubmed/34136369",
                "http://www.ncbi.nlm.nih.gov/pubmed/34060939",
                "http://www.ncbi.nlm.nih.gov/pubmed/33813531",
                "http://www.ncbi.nlm.nih.gov/pubmed/33804005"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36211205",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Nephrogenic systemic fibrosis typically occurs in patients with renal failure and is strongly associated with gadolinium exposure through stimulation of macrophage-activated fibrosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36075185",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "text": "Intravenous administration of gadolinium-based contrast agents (GBCA) in patients with impaired renal function has been of concern to primary care physicians due to the potential worsening of renal dysfunction and nephrogenic systemic fibrosis (NSF).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35532771",
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 734,
                    "text": "Following transplantation, she underwent a cerebral MRI with injection of a gadolinium-based contrast agent (GBCA) in the work-up for Schwartz-Bartter syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35167789",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "text": "Nephrogenic systemic fibrosis (NSF) is a rare disease that can present in patients with kidney injury who have been exposed to gadolinium-based contrast agents (GBCAs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34997298",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Gadoxetic acid (GA) is a half-biliary excreted gadolinium-based contrast agent (GBCA) administered at lower dose than gadobenic acid with similar ionic structure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34997298",
                    "offsetInBeginSection": 1268,
                    "offsetInEndSection": 1424,
                    "text": "No cases of NSF were documented in this study related to gadoxetic acid use in oncology patients, including those with moderate and severe renal impairment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34848324",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 242,
                    "text": "The purpose of this study was to systematically search for long-term complications, including Nephrogenic Systemic Fibrosis (NSF), in patients who were previously administered the gadolinium-based contrast agent Gadofosveset at our institute.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34136369",
                    "offsetInBeginSection": 163,
                    "offsetInEndSection": 332,
                    "text": "Nephrogenic systemic fibrosis (NSF) with GBCAs has been a deterrent for the physician and has led to avoidance of these agents in patients with impaired kidney function.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34060939",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 287,
                    "text": "A 66-year-old male patient with end-stage chronic kidney disease undergoing maintenance dialysis and with a history of group I intravenous gadolinium-based contrast media (GBCM) administration presented with clinical and pathologic findings consistent with nephrogenic systemic fibrosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33813531",
                    "offsetInBeginSection": 523,
                    "offsetInEndSection": 809,
                    "text": "MRI brain was repeated with gadoxetate contrast to minimize the risk of nephrogenic systemic fibrosis (NSF) in a patient with severe renal disease and this revealed an intracranial empyema involving both the trigeminal and abducens nerves confirming the diagnosis of Gradenigo syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What medical proceedure causes nephrogenic systemic fibrosis?",
            "type": "factoid",
            "id": "67e93f2d18b1e36f2e0000db",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39231856"
            ],
            "snippets": [],
            "body": "What cancer hallmarks are characteristically promoted by tumor microenvironment components, such as pericytes?",
            "type": "list",
            "id": "680c137818b1e36f2e000158",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33052445",
                "http://www.ncbi.nlm.nih.gov/pubmed/31659856",
                "http://www.ncbi.nlm.nih.gov/pubmed/31583453",
                "http://www.ncbi.nlm.nih.gov/pubmed/31309339",
                "http://www.ncbi.nlm.nih.gov/pubmed/35382390",
                "http://www.ncbi.nlm.nih.gov/pubmed/29961234",
                "http://www.ncbi.nlm.nih.gov/pubmed/31262329",
                "http://www.ncbi.nlm.nih.gov/pubmed/29885536"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33052445",
                    "offsetInBeginSection": 819,
                    "offsetInEndSection": 876,
                    "text": "Peak incidence was observed in the age range 55-69 years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31659856",
                    "offsetInBeginSection": 1155,
                    "offsetInEndSection": 1264,
                    "text": "The respective mean age and median duration of disease was 57  8 and 2.0 years (interquartile range 1.5-2.7).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31583453",
                    "offsetInBeginSection": 861,
                    "offsetInEndSection": 948,
                    "text": "The SSc-ILD, IIM-ILD, and IPAF groups had similar features: average age in the mid-50s,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31309339",
                    "offsetInBeginSection": 1722,
                    "offsetInEndSection": 1865,
                    "text": "Younger age of onset and high prevalence of Scl-70 antibody are unique South Asian features common with large Indian, Thai, and Chinese series.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35382390",
                    "offsetInBeginSection": 681,
                    "offsetInEndSection": 908,
                    "text": "The mean age at onset was significantly lower in Iranian patients (35.58  11.68 vs 47.06  13.54, It seems that systemic sclerosis occurred in younger ages among Iranian female with the predominance of diffuse cutaneous subtype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29961234",
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 782,
                    "text": "The peak age of onset was 55-69 years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Typical age range of onset of systemic scleroderma.",
            "type": "factoid",
            "id": "67e26d6218b1e36f2e000074",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39106696",
                "http://www.ncbi.nlm.nih.gov/pubmed/38107131",
                "http://www.ncbi.nlm.nih.gov/pubmed/37852051",
                "http://www.ncbi.nlm.nih.gov/pubmed/39492373",
                "http://www.ncbi.nlm.nih.gov/pubmed/37570348",
                "http://www.ncbi.nlm.nih.gov/pubmed/37237093",
                "http://www.ncbi.nlm.nih.gov/pubmed/38007543",
                "http://www.ncbi.nlm.nih.gov/pubmed/37689928",
                "http://www.ncbi.nlm.nih.gov/pubmed/37269793",
                "http://www.ncbi.nlm.nih.gov/pubmed/36360129"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39106696",
                    "offsetInBeginSection": 403,
                    "offsetInEndSection": 626,
                    "text": "Five chicken genotypes were employed in each trial: 2 Italian local breeds, Bionda Piemontese (BP) and Robusta Maculata (RM), along with their crossbreeds with Sasso hens (BPSA and RMSA), and a commercial hybrid (Ross 308).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38107131",
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 839,
                    "text": "Lollo Rossa (LR) and Lollo Bionda (LB), in the nutrient film technique (NFT) hydroponic system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37852051",
                    "offsetInBeginSection": 605,
                    "offsetInEndSection": 715,
                    "text": "local poultry strains, Bionda Piemontese (BP), Robusta Maculata (RM), BP x Sasso (BPxS), and RM x Sasso (RMxS)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39492373",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "text": "Growth performance and meat quality were assessed in 238 chicks of both sexes belonging to a commercial crossbreed (Ross 308), and 2 Italian local breeds (Bionda Piemontese-BP and Robusta Maculata-RM).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37570348",
                    "offsetInBeginSection": 464,
                    "offsetInEndSection": 622,
                    "text": "The present study aimed at evaluating the growth performance and slaughter traits of two local Italian chicken breeds (Bionda Piemontese and Robusta Maculata)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237093",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 479,
                    "text": "The aim of this study was to investigate the effect of different light spectra: red (656 nm), blue (450 nm), red/blue (3:1), and white (peak at 449 nm) on biochemical properties, photosynthesis and gene expression in two lettuce cultivars (Lollo Rossa and Lollo Bionda) grown under different methods of nutrient solution replacement in hydroponics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is BIONDA",
            "type": "factoid",
            "id": "67fa3c5818b1e36f2e000109",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39714111",
                "http://www.ncbi.nlm.nih.gov/pubmed/39690788",
                "http://www.ncbi.nlm.nih.gov/pubmed/39655780",
                "http://www.ncbi.nlm.nih.gov/pubmed/39617281",
                "http://www.ncbi.nlm.nih.gov/pubmed/39571959",
                "http://www.ncbi.nlm.nih.gov/pubmed/39566199",
                "http://www.ncbi.nlm.nih.gov/pubmed/39558879",
                "http://www.ncbi.nlm.nih.gov/pubmed/39548653",
                "http://www.ncbi.nlm.nih.gov/pubmed/39537633",
                "http://www.ncbi.nlm.nih.gov/pubmed/39528474"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39714111",
                    "offsetInBeginSection": 369,
                    "offsetInEndSection": 508,
                    "text": "Oligodendrocytes are glial cells found within the central nervous system involved in the production of myelin and the myelination of axons.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39690788",
                    "offsetInBeginSection": 1096,
                    "offsetInEndSection": 1422,
                    "text": "Transplanted hOPCs can survive in periventricular and subcortical white matter. Further, transplanted hOPCs expressed markers of mature oligodendrocytes (MBP and MAG) and few cells expressed markers of preoligodendrocytes (NG2 and A2B5), suggesting that these cells can differentiate into mature oligodendrocytes in the brain.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39655780",
                    "offsetInBeginSection": 946,
                    "offsetInEndSection": 1097,
                    "text": "Moreover, the nanobodies were characterised in imaging applications and as intrabodies, expressed in mammalian cells, such as primary oligodendrocytes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39617281",
                    "offsetInBeginSection": 826,
                    "offsetInEndSection": 1064,
                    "text": "Furthermore, we summarize the natural products and herbal medicine currently employed in remyelination along with their mechanisms of action, highlighting the potential and challenges of certain natural compounds to enhance myelin repair.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39571959",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Myelination is the process by which oligodendrocytes ensheathe axons to form myelin sheaths.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39566199",
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1092,
                    "text": "the number and length of myelin sheaths produced by mature oligodendrocytes were unaffected.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39558879",
                    "offsetInBeginSection": 41,
                    "offsetInEndSection": 139,
                    "text": "axonal myelination, executed by mature oligodendrocytes (MOLs), enables rapid neural transmission.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39548653",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "text": "Oligodendrocytes (OLGs) are the myelin-producing cells in the central nervous system (CNS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39548653",
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 410,
                    "text": "Upon injury, the damaged CNS repopulates the lesion with oligodendrocyte precursor cells (OPCs) that consequently mature into OLGs to repair the myelin damage and prevent further axonal loss.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39537633",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "Oligodendrocytes are critical for CNS myelin formation and are involved in preterm-birth brain injury (PBI) and multiple sclerosis (MS), both of which lack effective treatments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What glial cells are responsible for myelination in the CNS?",
            "type": "factoid",
            "id": "680a21eb18b1e36f2e000150",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39114870",
                "http://www.ncbi.nlm.nih.gov/pubmed/38358339",
                "http://www.ncbi.nlm.nih.gov/pubmed/38262242",
                "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
                "http://www.ncbi.nlm.nih.gov/pubmed/30595754",
                "http://www.ncbi.nlm.nih.gov/pubmed/37276871",
                "http://www.ncbi.nlm.nih.gov/pubmed/38266541",
                "http://www.ncbi.nlm.nih.gov/pubmed/38726843",
                "http://www.ncbi.nlm.nih.gov/pubmed/37952913",
                "http://www.ncbi.nlm.nih.gov/pubmed/36914633"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39114870",
                    "offsetInBeginSection": 278,
                    "offsetInEndSection": 395,
                    "text": "Zanidatamab is an antibody designed to destroy cancer cells that have higher-than-normal HER2 protein or gene levels.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38358339",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of HER2-amplified/expressing solid tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38262242",
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 484,
                    "text": "Zanidatamab (ZW25), a humanized, bispecific antibody that simultaneously binds the 2 distinct HER2 epitopes bound by trastuzumab and pertuzumab, has demonstrated safety and activity in HER2+ tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 402,
                    "text": "Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30595754",
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 685,
                    "text": "ZW25, a bispecific HER2-directed antibody targeting the extracellular domains 2 and 4, showed excellent tolerability and considerable single-agent activity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37276871",
                    "offsetInBeginSection": 72,
                    "offsetInEndSection": 306,
                    "text": "Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited tolerability and preliminary anti-tumour activity in HER2-expressing or HER2 (also known as ERBB2)-amplified treatment-refractory biliary tract cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38266541",
                    "offsetInBeginSection": 885,
                    "offsetInEndSection": 1029,
                    "text": "Various anti-HER2 therapies, including trastuzumab, pertuzumab, trastuzumab-deruxtecan, zanidatamab and neratinib, have undergone investigation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38726843",
                    "offsetInBeginSection": 820,
                    "offsetInEndSection": 1032,
                    "text": "Emerging treatments such as trastuzumab deruxtecan (T-DXd), zanidatamab and evorpacept further illustrate the ongoing efforts to leverage unique mechanisms of action for improved HER2-positive antitumor activity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37952913",
                    "offsetInBeginSection": 975,
                    "offsetInEndSection": 1190,
                    "text": "This agent is currently evaluated in phase 3 study (DESTINY-Gastric04 trial), as are several other anti-HER2 (zanidatamab, margetuximab, tucatinib), immune checkpoint inhibitors, or targeted therapies (anti-FGFR2b).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
                    "offsetInBeginSection": 2690,
                    "offsetInEndSection": 2830,
                    "text": "These results support that HER2 is an actionable target in various cancer histologies, including biliary tract cancer and colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the gene target for  Zanidatamab?",
            "type": "factoid",
            "id": "67fb046e18b1e36f2e00010c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39728013",
                "http://www.ncbi.nlm.nih.gov/pubmed/39730382",
                "http://www.ncbi.nlm.nih.gov/pubmed/39731054",
                "http://www.ncbi.nlm.nih.gov/pubmed/39741336"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728013",
                    "offsetInBeginSection": 927,
                    "offsetInEndSection": 1025,
                    "text": "A comprehensive analysis of laboratory and molecular tests was performed to confirm HIV infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730382",
                    "offsetInBeginSection": 765,
                    "offsetInEndSection": 970,
                    "text": " Approximately 85% reported on the test outcome; 2.3% (n = 825) were reactive, and 75.8% came for test confirmation. After the confirmation test, a concordance of 85% was found with the national algorithm.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39731054",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "HIV indicator condition-guided testing is recommended by guidelines to identify undiagnosed HIV infections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39731054",
                    "offsetInBeginSection": 1678,
                    "offsetInEndSection": 1873,
                    "text": "The most frequently tested HIV indicator conditions were unexplained weight loss (n = 13, 41.9%), unexplained lymphadenopathy (n = 8, 38.1%), and sexually transmitted infections (n = 161, 33.2%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39741336",
                    "offsetInBeginSection": 680,
                    "offsetInEndSection": 926,
                    "text": "Given positive HIV and syphilis antibody in serological examination, normal spinal cord MRI and electromyogram, and after excluding other potential diagnoses through comprehensive analysis, the diagnosis of HIV-related myelopathy was established.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39731054",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 821,
                    "text": "The intervention consisted of HIV expert led education for GPs with a stepwise implementation of point-of-care testing (phase 1), followed by adding peer-to-peer case feedback by trained GP ambassadors (phase 2).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "How do you diagnose HIV infection?",
            "type": "summary",
            "id": "67d6bbfa18b1e36f2e000020",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39337432",
                "http://www.ncbi.nlm.nih.gov/pubmed/39394900",
                "http://www.ncbi.nlm.nih.gov/pubmed/39543265",
                "http://www.ncbi.nlm.nih.gov/pubmed/39436849",
                "http://www.ncbi.nlm.nih.gov/pubmed/39541331",
                "http://www.ncbi.nlm.nih.gov/pubmed/39681147"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39337432",
                    "offsetInBeginSection": 780,
                    "offsetInEndSection": 907,
                    "text": "The total number of observed changes included 722 SNPs, 12 mutations, 62 indels, 5 indel mutations, and 35 heteroplasmic sites.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39394900",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Germline pathogenic mutation of the BRCA gene increases the prevalence of breast cancer. Reports on the benign variants of BRCA genes are limited.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39394900",
                    "offsetInBeginSection": 250,
                    "offsetInEndSection": 357,
                    "text": "Therefore, in the present study, we focused on benign single nucleotide polymorphisms (SNPs) of BRCA genes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39394900",
                    "offsetInBeginSection": 1258,
                    "offsetInEndSection": 1374,
                    "text": "In conclusion, linkage disequilibrium from benign SNPs of the BRCA genes potentially affects cancer characteristics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39543265",
                    "offsetInBeginSection": 717,
                    "offsetInEndSection": 1220,
                    "text": "Subjects were genotyped for ABCC11 SNPs, and their haplotypes were correlated with axilla microbiome DNA sequencing profiles and predicted metagenome functions. A multigeneration family pedigree revealed a Mendelian autosomal recessive pattern: the C allele of ABCC11 correlated with bacterial Cys-S-conjugate -lyase (PatB) gene known for Staphylococcus hominis biosynthesis of 3M3SH from human precursor; PatB was rescinded in hosts with homozygous TT alleles encoding ABCC11 loss-of-function mutation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39436849",
                    "offsetInBeginSection": 886,
                    "offsetInEndSection": 1127,
                    "text": "We also identified an additional 24 and 40 single nucleotide polymorphisms as well as 6 and 2 insertions or deletions in various virulence genes that are likely to be associated with changes in drug susceptibility in L2 and L4, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39541331",
                    "offsetInBeginSection": 708,
                    "offsetInEndSection": 918,
                    "text": "Through various bioinformatics tools, we detected 47900 nsSNPs, particularly K142M, I151N, M179R, S184L, L189P, and C321R, which were found to be the most deleterious variants, decreasing the protein stability.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39681147",
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 529,
                    "text": "The g.61695680 T > C synonymous mutation significantly altered the RNA secondary structure and stability of R3HDM1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39541331",
                    "offsetInBeginSection": 97,
                    "offsetInEndSection": 242,
                    "text": "Mutations in the tyrosinase gene can disrupt the hydroxylation of tyrosine, leading to decreased production of 3,4-dihydroxyphenylalanine (DOPA).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is a single-nucleotide polymorphism (SNP) the same as a mutation?",
            "type": "yesno",
            "id": "680fe1e3353a4a2e6b00000f",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39740315",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739012",
                "http://www.ncbi.nlm.nih.gov/pubmed/39715268",
                "http://www.ncbi.nlm.nih.gov/pubmed/39704359",
                "http://www.ncbi.nlm.nih.gov/pubmed/39669866",
                "http://www.ncbi.nlm.nih.gov/pubmed/39668879",
                "http://www.ncbi.nlm.nih.gov/pubmed/39665997",
                "http://www.ncbi.nlm.nih.gov/pubmed/39662871",
                "http://www.ncbi.nlm.nih.gov/pubmed/39654297",
                "http://www.ncbi.nlm.nih.gov/pubmed/39652058"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740315",
                    "offsetInBeginSection": 988,
                    "offsetInEndSection": 1129,
                    "text": "Most focused on anorexia nervosa (AN), some on treatment-resistant cases, and others on bulimia nervosa (BN) and binge eating disorder (BED).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739012",
                    "offsetInBeginSection": 852,
                    "offsetInEndSection": 1104,
                    "text": "Six of the 25 treatments demonstrated a higher response rate versus placebo or sham treatment: electroconvulsive therapy (ECT), minocycline, theta-burst stimulation (TBS), repetitive transcranial magnetic stimulation (rTMS), ketamine, and aripiprazole.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39715268",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "Although electroconvulsive therapy (ECT) is effective for treating depression, schizophrenia, and mania,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39704359",
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 355,
                    "text": "The study utilized quantitative consciousness and quantitative nociceptive indices for monitoring sedation, hypnosis, and nociceptive responses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39669866",
                    "offsetInBeginSection": 486,
                    "offsetInEndSection": 568,
                    "text": "He was initially diagnosed with major depressive disorder with catatonic features.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39668879",
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 568,
                    "text": "The number courses of ECT for bipolar depression (n = 202) exceeded those for mania/mixed episodes (n = 123).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39668879",
                    "offsetInBeginSection": 697,
                    "offsetInEndSection": 804,
                    "text": "No significant difference was seen in response to ECTs between bipolar depression and mania/mixed episodes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39665997",
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 586,
                    "text": "ECT was as likely to be given for non-affective psychoses (37.7%), as for affective psychoses (35.0%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39665997",
                    "offsetInBeginSection": 587,
                    "offsetInEndSection": 664,
                    "text": "ECT was also administered for confusional states and non-psychotic disorders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39662871",
                    "offsetInBeginSection": 844,
                    "offsetInEndSection": 955,
                    "text": "Catatonia (64.5%) and treatment-resistant depressive disorder (35.5%) were the most common indications for ECT.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Indications for Electro-convulsive therapy.",
            "type": "list",
            "id": "6810c54b353a4a2e6b000011",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37686092",
                "http://www.ncbi.nlm.nih.gov/pubmed/39549128",
                "http://www.ncbi.nlm.nih.gov/pubmed/38692109",
                "http://www.ncbi.nlm.nih.gov/pubmed/38605523",
                "http://www.ncbi.nlm.nih.gov/pubmed/37616578",
                "http://www.ncbi.nlm.nih.gov/pubmed/35849035",
                "http://www.ncbi.nlm.nih.gov/pubmed/35804976",
                "http://www.ncbi.nlm.nih.gov/pubmed/37914076",
                "http://www.ncbi.nlm.nih.gov/pubmed/38553638",
                "http://www.ncbi.nlm.nih.gov/pubmed/33601293"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37686092",
                    "offsetInBeginSection": 1446,
                    "offsetInEndSection": 1681,
                    "text": "Genetic alterations common in glioblastoma, IDH-wildtype, were seen in two cases with available NGS data, including EGFR gene amplification, TERT promoter mutation, PTEN mutation, trisomy of chromosome 7, and monosomy of chromosome 10.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39549128",
                    "offsetInBeginSection": 532,
                    "offsetInEndSection": 618,
                    "text": "Single nucleotide variants (SNV), amplification, or chromosome 7 polysomy were sought.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38692109",
                    "offsetInBeginSection": 107,
                    "offsetInEndSection": 257,
                    "text": "In particular, in glioblastoma, EGFR amplification emerges as a catalyst for invasion, proliferation, and resistance to radiotherapy and chemotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38605523",
                    "offsetInBeginSection": 281,
                    "offsetInEndSection": 574,
                    "text": "To determine whether these tumors are more closely related to traditionally defined EGFR-amplified or nonamplified gliomas, a retrospective search identified 22 out of 1143 (1.9%) gliomas with an average of 5 copies/cell of EGFR and CEP7 with an EGFR/CEP7 ratio of <2 displaying high polysomy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37616578",
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 216,
                    "text": "EGFR gene amplification or mutation is frequently detected in GBMs and is associated with poor prognosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35849035",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35804976",
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 404,
                    "text": "Glioblastoma must have wild-type IDH gene and some characteristics, such as TERT promoter mutation, EGFR gene amplification, microvascular proliferation, among others.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37914076",
                    "offsetInBeginSection": 739,
                    "offsetInEndSection": 831,
                    "text": "EGFR gene amplification and telomerase reverse transcriptase gene promoter (TERTp) mutation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38553638",
                    "offsetInBeginSection": 762,
                    "offsetInEndSection": 938,
                    "text": "The glioblastoma immunohistochemistry phenotype was confirmed by EGFR and cMet gene amplification in the tumor parallel to the detection of HCMV IE and UL69 genes and proteins.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33601293",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "In the EORTC 1410/INTELLANCE 2 randomised, phase II study (NCT02343406), with the antibody-drug conjugate depatuxizumab mafodotin (Depatux-M, ABT-414) in patients with recurrent EGFR-amplified glioblastoma,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is a common chromosome-level gain in glioblastoma?",
            "type": "factoid",
            "id": "67fd5d6518b1e36f2e000138",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38794660",
                "http://www.ncbi.nlm.nih.gov/pubmed/35923207",
                "http://www.ncbi.nlm.nih.gov/pubmed/35634367",
                "http://www.ncbi.nlm.nih.gov/pubmed/39041388",
                "http://www.ncbi.nlm.nih.gov/pubmed/34202781",
                "http://www.ncbi.nlm.nih.gov/pubmed/39037117",
                "http://www.ncbi.nlm.nih.gov/pubmed/32759654",
                "http://www.ncbi.nlm.nih.gov/pubmed/37257176",
                "http://www.ncbi.nlm.nih.gov/pubmed/32854220",
                "http://www.ncbi.nlm.nih.gov/pubmed/38136041"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38794660",
                    "offsetInBeginSection": 532,
                    "offsetInEndSection": 598,
                    "text": "human breast milk constitutes the main natural source of melatonin",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35923207",
                    "offsetInBeginSection": 899,
                    "offsetInEndSection": 1082,
                    "text": "Many antioxidants have been found in human milk, including superoxide dismutase, glutathione peroxidase, glutathione, vitamins, melatonin, short-chain fatty acids, and phytochemicals.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35634367",
                    "offsetInBeginSection": 793,
                    "offsetInEndSection": 952,
                    "text": "Hormones, such as glucocorticoids and melatonin, transfer from the mother's plasma to milk, and then the infant is exposed to circadian cues from their mother.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39041388",
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1100,
                    "text": "Melatonin concentration exhibited a consistent pattern, being higher at night, and elevated in colostrum.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34202781",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 209,
                    "text": "Melatonin is an active molecule that is present in the breast milk produced at night beginning in the first stages of lactation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39037117",
                    "offsetInBeginSection": 1078,
                    "offsetInEndSection": 1133,
                    "text": "night milk has high levels of melatonin and tryptophan,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38794660",
                    "offsetInBeginSection": 600,
                    "offsetInEndSection": 793,
                    "text": "diurnal dynamic changes, an acrophase early after midnight, and changes in melatonin concentrations according to gestational age and during the different stages of lactation have been reported.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759654",
                    "offsetInBeginSection": 1111,
                    "offsetInEndSection": 1244,
                    "text": "Significant circadian variation is found in tryptophan, fats, triacylglycerol, cholesterol, iron, melatonin, cortisol, and cortisone.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37257176",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "High-Temperature Pasteurization Used at Donor Breast Milk Banks Reduces Melatonin Levels in Breast Milk.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32854220",
                    "offsetInBeginSection": 683,
                    "offsetInEndSection": 975,
                    "text": "melatonin (ELISA). Mixed random-effects linear regression models were used to study the influence of maternal and gestational ages on BM antioxidants, adjusted by days of lactation. Regression models evidenced a negative association between maternal age and BM melatonin levels ( = -7.4  2.5;",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Melatonin found in human milk?",
            "type": "summary",
            "id": "680d5dd8353a4a2e6b000004",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39648330",
                "http://www.ncbi.nlm.nih.gov/pubmed/39524724",
                "http://www.ncbi.nlm.nih.gov/pubmed/39325960",
                "http://www.ncbi.nlm.nih.gov/pubmed/39286984",
                "http://www.ncbi.nlm.nih.gov/pubmed/39282450",
                "http://www.ncbi.nlm.nih.gov/pubmed/39026725",
                "http://www.ncbi.nlm.nih.gov/pubmed/38955087",
                "http://www.ncbi.nlm.nih.gov/pubmed/38870061",
                "http://www.ncbi.nlm.nih.gov/pubmed/38519642",
                "http://www.ncbi.nlm.nih.gov/pubmed/38398085"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39648330",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Accumulating evidence suggests that phenotype switching of cancer cells is essential for therapeutic resistance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39648330",
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 491,
                    "text": "Exposure of B16F10 cells to staurosporine induced a hyperdifferentiated phenotype associated with transient drug tolerance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39524724",
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 325,
                    "text": "intratumour phenotypic heterogeneity arising from the bi-directional interplay between plastic cancer cells and the microenvironment has been identified as key to disease progression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39524724",
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1165,
                    "text": "Consequently, TPC1 KO melanoma cells exhibit reduced proliferation and invasiveness, as well as increased pigmentation associated with nuclear localisation of the MITF-related transcription factor TFEB.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39325960",
                    "offsetInBeginSection": 512,
                    "offsetInEndSection": 647,
                    "text": "TCTN1 promoted melanoma invasion and migration in vitro and distant metastasis in vivo and induced a mesenchymal-like phenotype switch.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39325960",
                    "offsetInBeginSection": 835,
                    "offsetInEndSection": 977,
                    "text": "TCTN1-mediated FAO activated the p38/MAPK signaling pathway in melanoma cells, promoting tumor epithelial-mesenchymal transition and stemness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39286984",
                    "offsetInBeginSection": 401,
                    "offsetInEndSection": 593,
                    "text": "Switching pericyte phenotype from a synthetic to a differentiated state reverses immune suppression and sensitizes tumors to adoptive T cell therapy, leading to regression of melanoma in mice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39286984",
                    "offsetInBeginSection": 594,
                    "offsetInEndSection": 680,
                    "text": "In melanoma patients, improved survival is correlated with enhanced pericyte maturity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39286984",
                    "offsetInBeginSection": 681,
                    "offsetInEndSection": 910,
                    "text": "Importantly, pericyte plasticity is regulated by signaling pathways converging on Rho kinase activity, with pericyte maturity being inducible by selective low-dose therapeutics that suppress pericyte MEK, AKT, or notch signaling.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39282450",
                    "offsetInBeginSection": 540,
                    "offsetInEndSection": 639,
                    "text": "MAFG induces a melanoma phenotype switch from a melanocytic state to a more dedifferentiated state.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is phenotype switching in melanoma?",
            "type": "summary",
            "id": "67fc381f18b1e36f2e00012f",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39741195",
                "http://www.ncbi.nlm.nih.gov/pubmed/39737308",
                "http://www.ncbi.nlm.nih.gov/pubmed/39735978",
                "http://www.ncbi.nlm.nih.gov/pubmed/39730175",
                "http://www.ncbi.nlm.nih.gov/pubmed/39725148",
                "http://www.ncbi.nlm.nih.gov/pubmed/39723380",
                "http://www.ncbi.nlm.nih.gov/pubmed/39721408",
                "http://www.ncbi.nlm.nih.gov/pubmed/39720721",
                "http://www.ncbi.nlm.nih.gov/pubmed/39713909",
                "http://www.ncbi.nlm.nih.gov/pubmed/39713349"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39741195",
                    "offsetInBeginSection": 627,
                    "offsetInEndSection": 821,
                    "text": "In the MC-38 colon cancer model, this synthetic prime-boost regimen induces rapid regression and cure of large established subcutaneous cancers via the use of a single tumor-specific neoantigen.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39737308",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 156,
                    "text": "WT1- and MUC1-Pulsed Dendritic Cells",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39735978",
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 423,
                    "text": "TAMs may promote tumor angiogenesis, cancer cell invasion and immunosuppression, or, alternatively, inhibit tumor progression via neoantigen presentation, tumoricidal reactive oxygen species generation and pro-inflammatory cytokine secretion.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730175",
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 1062,
                    "text": "The mutations in the antigen protein were such that the protein retained its immunogenicity and could still function as a neoantigen.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725148",
                    "offsetInBeginSection": 143,
                    "offsetInEndSection": 358,
                    "text": "Driver mutations represent promising immunogenic targets, but a comprehensive characterization of the AML neoantigen landscape and their impact on patient outcomes and the AML immune microenvironment remain unclear.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725148",
                    "offsetInBeginSection": 612,
                    "offsetInEndSection": 787,
                    "text": "Neoantigen analysis showed that indels triggered a higher abundance of neoantigens both in quantity and quality compared to single nucleotide variants (SNVs) and gene fusions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725148",
                    "offsetInBeginSection": 991,
                    "offsetInEndSection": 1193,
                    "text": "We validated 30 neoantigens through in vitro direct binding assays of predicted peptides to MHC proteins and confirmed the immunogenicity of 20 neoantigens using interferon- ELISpot and tetramer assays.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39723380",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 295,
                    "text": "Neoantigens from somatic mutations are central to many immunotherapeutic strategies and understanding their landscape in breast cancer is crucial for targeted interventions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39721408",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 173,
                    "text": "Neoantigens exclusively presented by human leukocyte antigens (HLAs) on cancer cell surfaces are newly discovered and highly cancer-specific biomarkers for cancer diagnosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39720721",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "Mutations commonly occur in cancer cells, arising neoantigen as potential targets for personalized immunotherapy of lung adenocarcinoma (LUAD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is a neoantigen?",
            "type": "summary",
            "id": "67c9e46881b1027333000004",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39527393",
                "http://www.ncbi.nlm.nih.gov/pubmed/39476083",
                "http://www.ncbi.nlm.nih.gov/pubmed/39430992",
                "http://www.ncbi.nlm.nih.gov/pubmed/39366433",
                "http://www.ncbi.nlm.nih.gov/pubmed/39219017",
                "http://www.ncbi.nlm.nih.gov/pubmed/38933627",
                "http://www.ncbi.nlm.nih.gov/pubmed/38780774",
                "http://www.ncbi.nlm.nih.gov/pubmed/38504530",
                "http://www.ncbi.nlm.nih.gov/pubmed/38345716",
                "http://www.ncbi.nlm.nih.gov/pubmed/38004096"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39527393",
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1338,
                    "text": "There is limited evidence to support the use of viscosupplementation, percutaneous needle tenotomy, and medicinal signaling cell-based therapies beyond platelet-rich plasma for anterior knee pain.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39476083",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 859,
                    "text": "non-operative treatment (physical therapy and hyaluronic acid [HA] being key drivers)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39476083",
                    "offsetInBeginSection": 1303,
                    "offsetInEndSection": 1345,
                    "text": "IA-HA and opioids were rarely recommended.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39430992",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 438,
                    "text": "The current study aimed to investigate the therapeutic effects of intra-articular injection of PRP and hyaluronic acid (HA) in the knee of people with knee osteoarthritis (KOA).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39430992",
                    "offsetInBeginSection": 833,
                    "offsetInEndSection": 1086,
                    "text": "Three month after the last injection (5th month) and after adjusting of baseline value using analysis of covariance, the mean of knee pain, stiffness, physical function and finally total score in the PRP group, was significantly lower than the HA group.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39430992",
                    "offsetInBeginSection": 1087,
                    "offsetInEndSection": 1287,
                    "text": "Regarding the Osteoarthritis grade, the mean of knee pain, Stiffness, Physical function and finally total score in the PRP group was significantly lower than the HA group in all Osteoarthritis grades.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39366433",
                    "offsetInBeginSection": 436,
                    "offsetInEndSection": 552,
                    "text": "Both viscosupplementation using hyaluronates and platelet-rich plasma injection show inconsistent long-term results.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39219017",
                    "offsetInBeginSection": 1280,
                    "offsetInEndSection": 1340,
                    "text": "Hyaluronic acid infiltrations are conditionally recommended.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38933627",
                    "offsetInBeginSection": 881,
                    "offsetInEndSection": 993,
                    "text": "Both PRP and HA injections significantly reduced pain and improved joint function in patients with advanced KOA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38933627",
                    "offsetInBeginSection": 1082,
                    "offsetInEndSection": 1149,
                    "text": "Both treatments showed similar improvements in functional outcomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do hyaluronic acid injections improve knee pain?",
            "type": "yesno",
            "id": "67fbe2ab18b1e36f2e000116",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39623612",
                "http://www.ncbi.nlm.nih.gov/pubmed/39580844",
                "http://www.ncbi.nlm.nih.gov/pubmed/39574094",
                "http://www.ncbi.nlm.nih.gov/pubmed/39470166",
                "http://www.ncbi.nlm.nih.gov/pubmed/39460779",
                "http://www.ncbi.nlm.nih.gov/pubmed/39422340",
                "http://www.ncbi.nlm.nih.gov/pubmed/39416654",
                "http://www.ncbi.nlm.nih.gov/pubmed/39412537",
                "http://www.ncbi.nlm.nih.gov/pubmed/39360759",
                "http://www.ncbi.nlm.nih.gov/pubmed/39725576"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39623612",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Alopecia areata (AA) is characterized by an autoimmune inflammatory response to hair follicles.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39580844",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "text": "Alopecia areata (AA) is one of the most common autoimmune hair diseases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39580844",
                    "offsetInBeginSection": 1556,
                    "offsetInEndSection": 1702,
                    "text": "The pathogenesis of alopecia areata is closely related to multiple genes and multiple pathways, in which keratin family genes may play a key role.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39574094",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "Androgenetic alopecia (AGA) stands as the most prevalent form of hair loss, affecting the hair follicles (HFs). Aging emerges as a prominent contributor in this condition.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39470166",
                    "offsetInBeginSection": 157,
                    "offsetInEndSection": 366,
                    "text": "Recent progress has significantly enhanced our understanding of the pathogenesis of AU. In particular, interferon- (IFN-) and interleukin (IL)-15 seem to play a pivotal role in the pathogenesis of the disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39460779",
                    "offsetInBeginSection": 357,
                    "offsetInEndSection": 709,
                    "text": "Our findings revealed distinct proteomic profiles between male AGA and female AGA, with a total of 68 differentially expressed proteins identified in male AGA and 84 in female AGA. Among these, specific proteins were altered in male AGA and female AGA, highlighting the sex-specific molecular pathways involved in the pathogenesis of pattern hair loss.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39422340",
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1184,
                    "text": "A total of 173 DEGs were obtained, mainly enriched in cytokines, chemokines, hair follicle development and hair cycle related signalling pathways.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39416654",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Numerous studies have linked vitamin D deficiency (VDD) to the pathogenesis of various alopecia disorders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39412537",
                    "offsetInBeginSection": 1254,
                    "offsetInEndSection": 1412,
                    "text": "IL-6 may cause a collapse of the hair bulb, having a significant part in the pathogenesis of alopecia indicating chronic inflammatory or autoimmune condition.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39360759",
                    "offsetInBeginSection": 404,
                    "offsetInEndSection": 548,
                    "text": "This review summarizes key AA disease mechanisms, current therapeutic methods, and emerging treatments, including Janus Kinase (JAK) inhibitors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Physiopathology of alopecia.",
            "type": "summary",
            "id": "67d7208218b1e36f2e00002e",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39546395",
                "http://www.ncbi.nlm.nih.gov/pubmed/33949692",
                "http://www.ncbi.nlm.nih.gov/pubmed/32759168",
                "http://www.ncbi.nlm.nih.gov/pubmed/30127505",
                "http://www.ncbi.nlm.nih.gov/pubmed/26119235",
                "http://www.ncbi.nlm.nih.gov/pubmed/21602806"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39546395",
                    "offsetInBeginSection": 370,
                    "offsetInEndSection": 428,
                    "text": "overexpression of the gliogenic transcription factor NFIA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33949692",
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 616,
                    "text": "Overexpressing the nuclear factor IB in hPSC-derived neural precursor cells induced a highly enriched astrocyte population in 2 weeks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168",
                    "offsetInBeginSection": 892,
                    "offsetInEndSection": 1009,
                    "text": "We demonstrate that paired-like homeodomain transcription factor 1 (PITX1) is critical for astrocyte differentiation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168",
                    "offsetInBeginSection": 1010,
                    "offsetInEndSection": 1128,
                    "text": "PITX1 overexpression induced early differentiation of astrocytes, and its knockdown blocked astrocyte differentiation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30127505",
                    "offsetInBeginSection": 98,
                    "offsetInEndSection": 285,
                    "text": "We demonstrate that overexpression of the transcription factors SOX9 and NFIB in human pluripotent stem cells rapidly and efficiently yields homogeneous populations of induced astrocytes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168",
                    "offsetInBeginSection": 1129,
                    "offsetInEndSection": 1319,
                    "text": "PITX1 overexpression also increased and PITX1 knockdown decreased expression of sex-determining region Y box 9 (SOX9), known initiator of gliogenesis, during early astrocyte differentiation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which transcription factors are important to define human astrocyte identity?",
            "type": "list",
            "id": "67eaf14c18b1e36f2e0000de",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39494584",
                "http://www.ncbi.nlm.nih.gov/pubmed/38970664",
                "http://www.ncbi.nlm.nih.gov/pubmed/37149260",
                "http://www.ncbi.nlm.nih.gov/pubmed/36534348",
                "http://www.ncbi.nlm.nih.gov/pubmed/30771154",
                "http://www.ncbi.nlm.nih.gov/pubmed/27703689",
                "http://www.ncbi.nlm.nih.gov/pubmed/27125812",
                "http://www.ncbi.nlm.nih.gov/pubmed/24166913",
                "http://www.ncbi.nlm.nih.gov/pubmed/23396800",
                "http://www.ncbi.nlm.nih.gov/pubmed/35077272"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39494584",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Peto's paradox, which highlights the lower-than-expected cancer rates in larger and/or longer-lived species,",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38970664",
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 298,
                    "text": "Despite this assumption, the observed uniformity in cancer rates across species, referred to as the Peto's paradox, presents a conundrum.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37149260",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 288,
                    "text": "The Peto's paradox consists in the observation that individuals from long-lived and large animal species do not experience a higher cancer incidence, despite being exposed for longer time to the possibility of accumulating mutations and having more target cells exposed to the phenomenon.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36534348",
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 338,
                    "text": "Early, scientists realized that the cancer incidence at the species level was not related to the number of cells or lifespan, a phenomenon called Peto's Paradox.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30771154",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 332,
                    "text": "Ageing is the leading risk factor for the emergence of cancer in humans. Accumulation of pro-carcinogenic events throughout life is believed to explain this observation; however, the lack of direct correlation between the number of cells in an organism and cancer incidence, known as Peto's Paradox, is at odds with this assumption.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27703689",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "Elucidation of tumour suppression mechanisms is a major challenge in cancer biology. Therefore, Peto's paradox, or low cancer incidence in large animals, has attracted focus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27125812",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "text": "Larger organisms tend to live longer, have more potentially carcinogenic cells, and undergo more cell divisions. While one might intuitively expect cancer incidence to scale with body size, this assertion does not hold over the range of different mammals.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24166913",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "text": "Peto's paradox is the counterintuitive finding that increasing body mass and thereby cell number does not correlate with an increase in cancer incidence across different species.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23396800",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 298,
                    "text": "If the occurrence of cancer is the result of a random lottery among cells, then body mass, a surrogate for cells number, should predict cancer incidence. Despite some support in humans, this assertion does not hold over the range of different natural animal species where cancer incidence is known.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23396800",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 446,
                    "text": "Explaining the so-called 'Peto's paradox' is likely to increase our understanding of how cancer defense mechanisms are shaped by natural selection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Peto's Paradox associated with cancer rates?",
            "type": "yesno",
            "id": "67c9e7ee81b1027333000007",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39475263",
                "http://www.ncbi.nlm.nih.gov/pubmed/39321508",
                "http://www.ncbi.nlm.nih.gov/pubmed/38775144",
                "http://www.ncbi.nlm.nih.gov/pubmed/38729514",
                "http://www.ncbi.nlm.nih.gov/pubmed/38552896",
                "http://www.ncbi.nlm.nih.gov/pubmed/39154706"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39475263",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 21,
                    "text": "The obligate anaerobe",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321508",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38775144",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 293,
                    "text": "Clostridioides (formerly Clostridium) difficile is a leading cause of infectious diarrhea associated with antibiotic therapy. The ability of this anaerobic pathogen to acquire enough iron to proliferate under iron limitation conditions imposed by the host largely determines its pathogenicity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38775144",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Functional characterization of Fur from the strict anaerobe Clostridioides difficile provides insight into its redox-driven regulatory capacity.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38729514",
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 371,
                    "text": "Fecal samples were inoculated into enrichment broth supplemented with taurocholate and cultured under anaerobic conditions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38552896",
                    "offsetInBeginSection": 450,
                    "offsetInEndSection": 711,
                    "text": "Among anaerobic spore-formers, genomic resources for pathogens including C. botulinum, C. difficile, and C. perfringens enable our capacity to identify common and unique factors that support their persistence in diverse reservoirs and capacity to cause disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Clostridioides difficile an aerobe or a anaerobe bacterium?",
            "type": "factoid",
            "id": "67d71d8f18b1e36f2e00002b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35447370"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35447370",
                    "offsetInBeginSection": 837,
                    "offsetInEndSection": 1040,
                    "text": "Abnormal vaginal discharge (n = 165, 61.8%), cervical columnar epithelial ectopy (n = 124, 46.4%), vaginal itching (n = 77, 28.8%), and lower abdominal pain (n = 61, 22.8%) were the predominant symptoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Symptoms of chlamydia genital infection in women.",
            "type": "list",
            "id": "67d7fded18b1e36f2e000042",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39739482",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739080",
                "http://www.ncbi.nlm.nih.gov/pubmed/39704031",
                "http://www.ncbi.nlm.nih.gov/pubmed/39695970",
                "http://www.ncbi.nlm.nih.gov/pubmed/39657770",
                "http://www.ncbi.nlm.nih.gov/pubmed/39736006",
                "http://www.ncbi.nlm.nih.gov/pubmed/39725322",
                "http://www.ncbi.nlm.nih.gov/pubmed/39725043",
                "http://www.ncbi.nlm.nih.gov/pubmed/39715044",
                "http://www.ncbi.nlm.nih.gov/pubmed/39665540"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739482",
                    "offsetInBeginSection": 1264,
                    "offsetInEndSection": 1317,
                    "text": "The most common organism was E coli and it was 52.5%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739080",
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 965,
                    "text": "E.coli was the predominant organism.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39704031",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "Escherichia coli is isolated in most of uncomplicated community-acquired urinary tract infections (UTI) and fosfomycin is one of the treatments of choice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39695970",
                    "offsetInBeginSection": 912,
                    "offsetInEndSection": 1096,
                    "text": "Escherichia coli (Ec) was the most commonly identified GNB (32.1%) and then Klebsiella pneumoniae (Kp) (25.3%), Pseudomonas aeruginosa (Pa) (13.9%) and Acinetobacter baumannii (10.5%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39657770",
                    "offsetInBeginSection": 1164,
                    "offsetInEndSection": 1276,
                    "text": "Escherichia Coli and Klebsiella Spp. were isolated in two-thirds of patients with leukocyte esterase positivity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39657770",
                    "offsetInBeginSection": 1277,
                    "offsetInEndSection": 1378,
                    "text": "The most common cause of UTI in patients with abnormal renal ultrasound findings was E. Coli (33.3%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Bacteria that most commonly causes urinary tract infection.",
            "type": "factoid",
            "id": "67e2b0a018b1e36f2e00008b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39729347",
                "http://www.ncbi.nlm.nih.gov/pubmed/39723481",
                "http://www.ncbi.nlm.nih.gov/pubmed/39722924",
                "http://www.ncbi.nlm.nih.gov/pubmed/39719404",
                "http://www.ncbi.nlm.nih.gov/pubmed/39717441",
                "http://www.ncbi.nlm.nih.gov/pubmed/39692694",
                "http://www.ncbi.nlm.nih.gov/pubmed/39691329",
                "http://www.ncbi.nlm.nih.gov/pubmed/39680453",
                "http://www.ncbi.nlm.nih.gov/pubmed/39645259",
                "http://www.ncbi.nlm.nih.gov/pubmed/39635824"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39729347",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 264,
                    "text": "Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists were superior to dipeptidyl peptidase-4 inhibitor and sulfonylurea for preventing kidney complications in patients with type 2 diabetes at moderate cardiovascular disease risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39729347",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 408,
                    "text": "Sodium-glucose cotransporter 2 inhibitor therapy compared favorably with glucagon-like peptide-1 receptor agonists for kidney disease outcomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39723481",
                    "offsetInBeginSection": 1004,
                    "offsetInEndSection": 1147,
                    "text": "SGLT2i showed the greatest benefits in reducing the risk of HHF (0.68 [0.64, 0.73]) and improving composite renal outcomes (0.67 [0.58, 0.77]),",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39722924",
                    "offsetInBeginSection": 1627,
                    "offsetInEndSection": 1722,
                    "text": "SGLT2 inhibitor shows significant improvement in glycemic profile in addition to lipid profile.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39722924",
                    "offsetInBeginSection": 1723,
                    "offsetInEndSection": 1767,
                    "text": "SGLT2 inhibitor lowered atherogenic indices.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39719404",
                    "offsetInBeginSection": 1403,
                    "offsetInEndSection": 1680,
                    "text": "SGLT2 inhibitors in patients with diabetes were independently associated with reduction in atherothrombotic major adverse cardiovascular events, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, and incident dialysis, compared with DPP-4 inhibitors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39717441",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Sodium-glucose cotransporter-2 (SGLT2) inhibitors afford significant cardiovascular benefits to patients with diabetes mellitus and heart failure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39717441",
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 378,
                    "text": "Three large randomized clinical trials (EMPAREG-Outcomes, DECLARE-TIMI58, and DAPA-HF) have shown that SGLT2 inhibitors prevent cardiovascular events and reduce the risk of death and hospital admission resulting from heart failure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39717441",
                    "offsetInBeginSection": 379,
                    "offsetInEndSection": 509,
                    "text": "Patients without type 2 diabetes mellitus (T2DM) also experience a similar degree of cardiovascular benefit as those with T2DM do.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39692694",
                    "offsetInBeginSection": 590,
                    "offsetInEndSection": 738,
                    "text": "SGLT2 inhibitors were associated with a significant reduction in heart failure hospitalization risk (adjusted HR 0.56, 95% CI 0.38-0.82, p = 0.028).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please list the benefits of sodium-glucose cotransporter 2 inhibitors",
            "type": "list",
            "id": "67cdb26a81b1027333000017",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39003345",
                "http://www.ncbi.nlm.nih.gov/pubmed/38904672",
                "http://www.ncbi.nlm.nih.gov/pubmed/38879179",
                "http://www.ncbi.nlm.nih.gov/pubmed/38044388",
                "http://www.ncbi.nlm.nih.gov/pubmed/37389790",
                "http://www.ncbi.nlm.nih.gov/pubmed/37196540"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39003345",
                    "offsetInBeginSection": 1040,
                    "offsetInEndSection": 1192,
                    "text": "We found some probiotic species, viz., Bacillus clausii, Lactobacillus curvatus, Vibrio mediterranei and Vibrio fluvialis, from the Sundarbans mangrove.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38904672",
                    "offsetInBeginSection": 524,
                    "offsetInEndSection": 946,
                    "text": "Probiotic strains isolated from pharmacy products including Lactobacillus sporogenes (strain not labeled), Lactobacillus rhamnosus GG (ATCC53103), Streptococcus faecalis (T-110 JPC), Bacillus mesentericus (TO-AJPC), Bacillus clausii (SIN) and Saccharomyces boulardii (CNCM I-745) were assessed for their probiotic traits including survival, antibiotic susceptibility, and antibacterial activity against pathogenic strains.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38879179",
                    "offsetInBeginSection": 392,
                    "offsetInEndSection": 566,
                    "text": "Bacillus subtilis SF106 and Bacillus clausii (recently renamed Shouchella clausii) SF174, two spore-forming strains previously characterised in vitro as potential probiotics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38879179",
                    "offsetInBeginSection": 735,
                    "offsetInEndSection": 1031,
                    "text": "Spores of both strains reduced the DSS-induced inflammation with spores of B. clausii SF174 more effective than B. subtilis SF106. Spores of both strains remodelled the mouse gut microbiota favouring the presence of beneficial microbes such as members of the Bacteroidetes and Akkermansia genera.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38044388",
                    "offsetInBeginSection": 282,
                    "offsetInEndSection": 345,
                    "text": "This study evaluates the use of Bacillus clausii (Enterogermina",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38044388",
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 1017,
                    "text": "Overall, 268 patients were enrolled; 99.6% of them were evaluated at T0 and 97.4% at T1, and safety was evaluated in 97.8% who had  1 dose of B. clausii.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37389790",
                    "offsetInBeginSection": 1015,
                    "offsetInEndSection": 1193,
                    "text": "Four clinical studies reported a reduction in oral mucositis occurrence with Lactobacillus species (Lactobacillus casei and Lactobacillus brevis CD2) and Bacillus clausii UBBC07.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Bacillus Clausii a probiotic?",
            "type": "yesno",
            "id": "67e090be18b1e36f2e00006c",
            "ideal_answer": "",
            "exact_answer": ""
        }
    ]
}
